New methods for studying complex diseases via genetic association studies by Schu, Matthew Charles
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2014
New methods for studying complex
diseases via genetic association
studies
https://hdl.handle.net/2144/15117
Boston University
BOSTON UNIVERSITY 
 
GRADUATE SCHOOL OF ARTS AND SCIENCES  
 
AND  
 
COLLEGE OF ENGINEERING 
 
 
 
 
 
Dissertation 
 
 
 
 
 
NEW METHODS FOR STUDYING COMPLEX DISEASES  
 
VIA GENETIC ASSOCIATION STUDIES 
 
 
 
by 
 
 
 
 
MATTHEW CHARLES SCHU 
 
B.S., The College of William and Mary, 2003 
M.S., Simmons College, 2006 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2014 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 © 2014 by 
  Matthew Charles Schu 
  All rights reserved  

 iv 
 
DEDICATION 
 I would like to dedicate this work to my family and friends who encouraged and 
supported me throughout this process and in all aspects of my education. Many thanks to 
all of the teachers, coaches, and mentors I have been fortunate enough to learn from over 
the years including Mr. Barrier, Mrs. Nickels, Mrs. Baldwin, Mr. Britcher, Carol and 
Johnny Clark, Coach Gerard, Professor Henson, and Professor Reilly. Special thanks also 
to Chris Murphy and Bill Barrett for giving a skinny kid from VA with a horrible 
collection of ties his first job out of college; and to Richard Park and David King for 
keeping me sane for these past 6 years. I thank my parents, Charles Schu and Janie 
Grinnan, for their continuous backing throughout this journey and my siblings, Chris and 
Sara Schu, whose personal successes inspire me to strive further in my own endeavors. 
Finally, I particularly want to thank my incredible fiancé (soon to be wife), Sarah, who 
believes in me even when I doubt myself and is generous with her advice, time, and 
praise always. 
  
 v 
 
ACKNOWLEDGMENTS  
 
This doctoral dissertation is a result of the tremendous support and guidance of 
several people, only a few of whom it is possible to mention here. First and foremost I 
want to thank my advisor, Dr. Lindsay Farrer, for giving me the opportunity to be a 
member of his exceptional research group. I am thankful for the multiple opportunities I 
received from Dr. Farrer to participate in both national and international collaborative 
projects  studying  the  genetics  of  Alzheimer’s  Disease (AD) and Age-related Macular 
Degeneration (AMD).  I appreciate his willingness to offer me his time, suggestions, and 
funding to make my Ph.D. experience productive and engaging. I want to thank the 
members of my thesis committee - Dr. Mark Kon, Dr. Simon Kasif, Dr. Clinton Baldwin 
and Dr. Luis Carvalho for their guidance and continuous support during the course of my 
graduate study. Additionally, I would like to thank Dr. Margaret DeAngelis for her 
boundless encouragement and for allowing me to collaborate with her in studying AMD 
genetics.  I would also like to thank Dr. Robert Green for giving me the opportunity to 
work with him on multiple review chapters regarding the field of genetic research in AD. 
Additionally, my colleagues and mentors in Dr. Farrer's lab group have contributed 
immensely to my academic and professional development at Boston University. I am 
grateful to Dr. Mark Logue, Dr. Gyungah Jun and Dr. Richard Sherva for providing their 
mentorship on several research projects that resulted in quality publications and helped 
advance my understanding of statistical genetics. I also express my gratitude to Dave 
King, Caroline Lyman and Johanna Squillacioti for their continuous administrative 
support during the course of the program at BU.   
 vi 
 
NEW METHODS FOR STUDYING COMPLEX DISEASES  
VIA GENETIC ASSOCIATION STUDIES 
MATTHEW CHARLES SCHU 
Boston University Graduate School of Arts and Sciences  
and College of Engineering, 2014 
 
Major Professor: Lindsay A. Farrer, Professor of Medicine (Biomedical Genetics), 
Neurology, Ophthalmology, Epidemiology, and Biostatistics 
 
ABSTRACT 
 
Genome-wide association studies (GWAS) have delivered many novel insights 
about the etiology of many common heritable diseases. However, in most disorders 
studied by GWAS, the known single nucleotide polymorphisms (SNPs) associated with 
the disease do not account for a large portion of the genetic factors underlying the 
condition.  This suggests that many of the undiscovered variants contributing to the risk 
of common diseases have weak effects or are relatively rare.  This thesis introduces novel 
adaptations of techniques for improving detection power for both of these types of risk 
variants, and reports the results of analyses applying these methods to real datasets for 
common diseases.   
Chapter 2 describes a novel approach to improve the detection of weak-effect risk 
variants that is based on an adaptive sampling technique known as Distilled Sensing (DS).  
This procedure entails utilization of a portion of the total sample to exclude from 
consideration regions of the genome where there is no evidence of genetic association, 
and then testing for association with a greatly reduced number of variants in the 
remaining sample.  Application of the method to simulated data sets and GWAS data 
 vii 
 
from studies of age-related macular degeneration (AMD) demonstrated that, in many 
situations, DS can have superior power over traditional meta-analysis techniques to detect 
weak-effect loci.  
Chapter 3 describes an innovative pipeline to screen for rare variants in next 
generation sequencing (NGS) data. Since rare variants, by definition, are likely to be 
present in only a few individuals even in large samples, efficient methods to screen for 
rare causal variants are critical for advancing the utility of NGS technology. Application 
of our approach, which uses family-based data to identify candidate rare variants that 
could explain aggregation of disease in some pedigrees, resulted in the discovery of novel 
protein-coding  variants  linked  to  increased  risk  for  Alzheimer’s  disease  (AD)  in  African  
Americans.   
The  techniques  presented  in  this  thesis  address  different  aspects  of  the  “missing  
heritability”  problem  and  offer efficient approaches to discover novel risk variants, and 
thereby facilitate development of a more complete picture of genetic risk for common 
diseases.     
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1. Contemporary methods for studying complex genetic disease 
 
1.1 Introduction Studying Complex Genetic Diseases 
 
Der Apffel felt nicht weit vom Baum. 
 – German Proverb 
1.1.1 Apples and Trees: Inheritance Patterns for Human Disease 
Broadly speaking, there are two types of transmission patterns by which heritable 
diseases are passed on from one generation to the next(Bamshad et al.).  Diseases that 
track completely with the transmission of variants in a single gene through a pedigree are 
called Mendelian diseases. In these scenarios, the genetic variants are said to be 100% 
penetrant and/or deterministic, meaning that if an individual has any of the deleterious 
genotypes associated with the condition then he or she will eventually develop the 
disease.  In many ways, the certainty of this type of inheritance pattern facilitates the 
discovery of the underlying genetic markers for the disease.  However, in reality this 
class of diseases makes up the minority of genetic disorders that are observed.  
The second type of genetic diseases follow what is known as a complex 
inheritance pattern. For such diseases, epidemiological studies can show with confidence 
that a certain variation in a gene may predispose an individual towards (or protect one 
from) developing a certain disease, however, possession of this variant is neither 
necessary nor sufficient for developing the disease.  Unlike deterministic variants for 
disease,  these  risk  alleles  only  affect  one’s  likelihood  for  developing  the  disease  at  some  
point in life.  In a family, complex diseases may appear to skip a generation, or present in 
one monozygotic twin but not her genetically identical sibling(Cirulli and Goldstein).  
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Because genetic risk factors have a more subtle effect on risk, discovering genetic 
associations is inherently more challenging in complex diseases than with Mendelian 
traits.  This dissertation will focus on ways to improve on existing techniques for finding 
novel genetic markers for complex heritable diseases.  
1.1.2 Measure Effect Size of Risk Alleles  
To quantify how much a risk allele predisposes an individual to a disease, 
geneticists often describe the effect size of a variant using an odds ratio (OR).  In a case-
control study, the OR for a particular genotype may be estimated by dividing the 
observed odds of having the disease among samples with this genotype by the observed 
odds of having the disease among samples with the reference genotype.  Hence, an OR=1 
indicates that there is no difference in disease risk between people who have the non-
reference genotype and the reference homozygotes. Meanwhile, an OR<1 indicates that 
people with the aberrant genotype are at a lower risk for the disease, i.e. the variant is 
protective, and an OR>1 indicates that the non-reference genotype increases  one’s  risk  
for the disease. In the latter case, the effect is said to be deleterious.   
1.1.3 Challenges  
While there is no upper limit on the magnitude of the observable effect size for a 
particular genetic variant, in practice an OR of 2 (reflecting that a having a given variant 
doubles one’s  odds of getting a certain disease) is considered sizable. This exposes two 
challenges inherent studying complex diseases.  First, the majority of the risk effect 
variants that have been discovered for common diseases have relatively weak effect on 
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risk,  with  OR’s  of  1.5  or  less(Wray, Goddard, and Visscher). This presents a challenge to 
researchers as for any given study design, as the power to detect a risk variant diminishes 
as the effect size of the variant also decreases. The second challenge arises from 
attempting to convey the effect of weak effect risk loci to individuals undergoing genetic 
testing for these alleles. Although geneticists and clinicians may have high confidence in 
the reproducibility of a variant and its effect size, often it is difficult to communicate 
these risks to patients in ways that allow patients to appropriately act (or not act) on this 
information(Christenhusz, Devriendt, and Dierickx; Roberts, Christensen, and Green).  
Typically, a GWAS finding for complex disease will offer more utility to a biologist 
trying to understand the molecular mechanisms of the disease, than a patient trying to 
assess his or her risk for the disorder.  Nonetheless, there is popular interest in the results 
of published genetic studies which creates a need for better methods for explaining the 
nuances of these findings to those uninitiated in the statistical methods typically used to 
describe such results.  
1.2 Motivating theory behind GWAS  
1.2.1 The Common Disease Common Variant Hypothesis 
The early rush to collect and analyze data for Genome-Wide Association Studies 
(GWAS) was driven by a widely accepted belief that the genetic underpinnings of 
common complex diseases could be attributed to a modest number of alleles that 
occurred relatively frequently in the population(Gibson,  “Rare  and  Common  Variants:  
Twenty  Arguments.”).  The so-called Common Disease-Common Variant hypothesis 
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(CDCV) also assumed that because the number genetic risk variants for any particular 
disease was not exceedingly large, then the few variants that did influence risk for disease 
had at least modest effect sizes(Manolio et al.).  Consequently, early GWAS studies were 
powered  to  detect  variants  with  OR’s  > 2. However, recent results from GWAS for many 
disorders suggest that this hypothesis is not entirely correct.  Nonetheless, the technology 
and methods that were developed predicated on the CDCV hypothesis yielded many 
insights into the genetics of common diseases.  
1.2.2 SNP-chip technology  
While the vast majority of the human genome is conserved between all 
individuals, about 0.1% of the genome varies from person to person. Decoding the secrets 
of this relatively small portion of our DNA is a goal of modern human genetics. One way 
to identify these variations is to focus specifically on single nucleotide polymorphisms 
(SNPs), or specific locations of the genome where a single unit of DNA is known to vary 
across the population. Our extensive knowledge of the locations of commonly occurring 
SNPs and ever-advancing hybridization platform technology have allowed for the capture 
of over 2 million of these variants on a single assay using modern SNP-chip technology.   
This technology is the cornerstone of a large class of GWAS experiments. The statistical 
models used for GWAS were similar to those used previously in candidate gene studies, 
and will be discussed at greater length in the next section.  However, one distinguishing 
feature of GWAS analysis is that the density of regions assayed on the SNP-chip allows 
for an agnostic screen of risk variants across the entire genome.    
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1.3 GWAS analysis methods  
1.3.1. Basic Methodology  
In the simplest study design, a GWAS involves sampling the DNA of a large 
cohort of patients presenting with a particular disease and a comparably sized cohort of 
controls, disease negative individuals, with similar characteristics (i.e. gender, ethnicity, 
and age for example).  Then by comparing allele frequencies of SNPs between the cases 
and controls, researchers are able to observe which SNPs exhibit significant enrichment 
for a particular allele in either the case or control group and infer that these loci flag 
regions of the genome that affect disease risk. A two-by-two contingency table can be 
constructed to reflect the frequency of the risk allele (generally assumed to be the less 
frequent or minor allele) between cases and controls. The significance of the difference in 
allelic frequencies between the two groups can be tested using a chi-square test with 1 
degree of freedom (df).  In this case, our null hypothesis is that there is no difference in 
allelic frequency for the SNP in question between cases and controls, or χ2 =1.  If we 
were testing just one SNP, then we would reject the null hypothesis if P(|𝑥ො|) < 0.05, 
where 𝑥 ∈ 𝑋~ χ2 with 1 df.   
1.3.2. Multiple testing burden  
Because millions of SNPs are tested in a GWAS, the odds of observing a 
nominally significant p-value (< 0.05) are very high just by chance.  Therefore, to protect 
against false positives, one must adjust for the number of independent tests that are 
performed.  Because each SNP is not necessarily independent of the next, rather than 
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adjusting for the total number of SNPs that are assayed in a particular GWAS (which we 
would be much too conservative) a preferred approach is to adjust for the number of 
distinct regions of linkage disequilibrium (LD) in the genome.  The generally accepted 
estimate of this number in most GWAS is 1 million LD regions, however this number has 
been estimated primarily from analysis of Caucasian genomes and therefore may differ 
substantially from the number of LD blocks in the genomes of other 
populations(International HapMap Consortium).  Assuming there are 1 million 
independent tests, the p-value threshold for genome-wide significance is 0.05/1,000,000 
or 5×10-8, using the Bonferroni method for multiple test correction. There are few other 
disciplines where the amount of evidence necessary to declare a statistically significant 
result is so formidable, yet this burden is a consequence of performing an agnostic screen 
at the genome level.   
1.3.3. Regression Techniques  
Many phenotypes, including those related to disease, are measurable on a 
continuous scale.  In this case, a linear regression model would allow for suitable 
statistical test.  When using a regression technique to model the effect of a SNP on a 
disease the first step to code each SNPs for the expected inheritance pattern (Table 1).   
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Table 1: Coding the genotype in a regression model 
 
 
 
 
In addition to allowing more flexibility in the decision of which heritability patterns to 
model, regression techniques also allow one to adjust for other covariates in the model 
which might explain some of the observed variance and thus improve the power to detect 
the variance attributed to genetic risk factors.  Returning to the scenario where one is 
studying a dichotomous phenotype, logistic regressions are appropriate for modeling 
case-control data assuming the samples are unrelated.  Whenever samples contain known 
biological relationships between individuals, neither linear nor logistic regression models 
are appropriate and one must use another method capable accounting for the correlated 
structure of family data, such as Generalized Estimating Equations (GEE) (Zeger, Liang, 
and Albert) or the Family-Based Association Test (FBAT) (Laird, Horvath, and Xu).    
1.4 Strength in Numbers: Methods for combining multiple GWAS data sets 
1.4.1 Meta-Analysis 
Given that for most complex diseases a large number of the discovered genetic 
risk variants have modest effect sizes (i.e. OR < 2) and that the threshold for identifying a 
variant as being genome-wide significant is very conservative (p < 5×10-8), it can be 
Heritability Pattern genotype 
(assuming A is the effect allele) AA AB BB 
recessive 1 0 0 
dominant 1 1 0 
additive 2 1 0 
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challenging to recruit a sufficiently large patient population in a single study that is 
sufficiently powered to detect novel genetic associations(Wray, Goddard, and Visscher). 
The curve in Figure 1 shows the result of power calculations for a hypothetical genetic 
risk variant that has an effect size of OR=1.5 and a minor allele frequency of 0.25 in the 
population.    
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Figure 1: Power as function of sample size for a GWAS 
 
 
Figure 1 shows the power curve for GWAS study assuming the SNP of interest has a 
causal effect on disease risk with and OR=1.5. Here we assume the trait of interest has a 
dichotomous phenotype and the SNP in question has a minor allele frequency of 0.25. 
We  use  a  significance  threshold  α=5×10-8, consistent with the standard threshold for 
genome-wide significance for SNPs identified by a GWAS. The horizontal red line 
indicates the a minimum power cutoff 1-β=0.8  corresponding  to  a  minimum  number  of  
4600 subjects (2300 cases and 2300 controls) needed to be enrolled in the study to 
achieve this power. Power calculations were performed in R, using the pbsize2() function 
available in the ‘gap’  package  which  is  downloadable  from  the  Comprehensive  R  
Archive Network (http://cran.r-project.org/web/packages/gap/index.html)(Jing et al.).   
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Because  the  significance  threshold,  α,  is  small  in  the  case  of  GWAS,  80%  power  
for identifying a variant with these characteristics is not achieved in until one can recruit 
a sample of at least 4600 subjects (assuming an equal number of unrelated cases and 
controls).  Even if the case of highly prevalent diseases, this is a daunting number of 
subjects for a single center to collect, diagnose, and genotype.  Thus, to achieve such a 
large number of samples for GWAS-related studies, researchers quickly developed 
methods for pooling resources and data.   
Combining data from multiple studies, even those studying the same disease, is 
not trivial.  Variability in how the data were collected, the technology used to obtain the 
genotypes, and genotype calling software, as well as subtle differences in the population 
substructure between recruitment sites, can lead to confounding batch effects that may 
corrupt the downstream analysis.  Therefore, in place of pooling all the data samples 
contributed from various collaborators and performing one GWAS (aka joint analysis), it 
is recommended that first each data set is analyzed separately and then the summary 
statistics from all these analyses are later combined to gain power. This approach, known 
as meta-analysis, reduces batch effects introduced by assaying samples on different SNP-
chip technology and allows each research team to individually adjust for site-specific 
confounding variables (such as population stratification), which may not need to be 
adjusted for in models applied to other data sets.  
1.4.2. The  Winner’s  Curse  and  the  Need  for  Replication   
In addition to combining data sets via meta-analysis, most GWA study designs 
also partition data into discovery and replication cohorts.  Replication is required in 
11 
 
 
 
GWAS analyses as effect size estimates from discovery sets tend to be inflations of the 
true effect sizes confirmed in follow-up studies(Ioannidis). The primary reason for this 
inflation is called the winner’s curse, resulting from the fact that the result may not have 
been observed if the actual (weaker) effect size was present in the sample. Furthermore, 
several other factors including sampling bias and flexible designs for statistical tests may 
contribute to over-fitting of GWAS data.  Therefore, to demonstrate the robustness of the 
result, most GWAS study designs include a replication step that includes evaluation of 
significantly associated loci from the discovery dataset in an independent sample(Hou 
and Zhao).  Because the number of SNPs tested in this latter stage is not as large, the 
burden of proof for declaring replication is well below the threshold set in the discovery 
stage (assuming replication data is analyzed separately from discovery data). For any 
results that replicate in this second stage, researchers typically meta-analyze the result 
from the discovery and replication analyses combined to better estimate the true effect 
size of a particular risk locus. The decision regarding which dataset to include in a 
discovery or replication group may be dictated by sample or funding availability, as there 
are different sample requirements and costs associated with using a SNP-chip array 
versus other genotyping assays. Regardless, to avoid reporting spurious results caused by 
the winner’s  curse, replication has become the accepted norm in publishing GWAS 
findings. 
12 
 
 
 
1.5 Less is More: Contemporary Methods for Variant Prioritization  
1.5.1. GWAS successes and shortcomings 
As of 1/11/2014, there were 12,170 SNPs, and 973 traits with 15,541 associations 
documented in the GWAS catalog, maintained by the National Human Genome Research 
Institute (NHGRI)(Hindorff et al.). Despite delivering many novel genetic insights into 
the etiology of common diseases, GWAS findings still leave a largely incomplete 
description of the genetic component of these conditions(Manolio et al.).  One 
explanation  for  this  “missing  heritability” problem is that the effect sizes of the 
undiscovered risk variants are, in fact, quite small and current GWAS study designs are 
underpowered to detect them.  One impediment to discovering novel weak-effect loci is 
the significance threshold which accompanies correcting for the number of multiple tests 
performed in an agnostic screen of the genome.  To circumvent this obstacle, many 
methods are available that prioritize variants or regions of the genome for follow-up 
replication studies.  Below is a brief description of contemporary methods for variant 
prioritization.  Chapter 2 describes a novel approach to variant prioritization in GWAS 
that uses Distilled Sensing(Haupt, Castro, and Nowak) to rule out large contiguous 
regions of the genome that show little to no evidence for association for a particular trait.  
This approach is of particular utility to researchers who wish to integrate their own data 
with existing GWAS and meta-analysis data sets.   
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1.5.2. SNP Prioritization Methods  
While standard SNP-chips assay a uniform distribution of variants throughout the 
genome, studies suggest that not all SNPs are equally likely to be functionally relevant.  
Work by Nicolae et al showed that eQTLs (SNPs that regulate the expression of mRNA 
or proteins) are significantly overrepresented in the catalogue genetic associations 
currated by the NHGRI(Nicolae et al.). Moreover, while most SNPs occur in non-coding 
regions, those that do fall within the gene can have varying effects on the proteins they 
encode.  For example, because of redundancy in the genetic code, not all changes in the 
DNA sequence (even in exonic regions) will result in changes in the amino acid sequence. 
Additionally, substitutions of amino acids that are structurally similar to each other are 
less likely to have an impact on protein function compared to more dissimilar exchanges 
of amino acid pairings. There are a variety of programs are available which predict the 
functional relevance of SNPs in protein coding regions(Ng and Henikoff; Adzhubei et 
al.), and these tools may also be used to prioritize SNPs that are more likely to be 
functionally relevant.  Combining evidence from multiple public data sources has been 
shown to offer superior predictive performance compared to using any one source 
individually.  CoVEC and FASTSNP, are two tools that integrate data from multiple 
functional  databases  to  make  a  final  prediction  on  the  severity  of  a  variant’s  effect  on  the  
protein structure or gene expression(Frousios et al.; Yuan et al.).  The former algorithm 
implements a support vector machine (SVM) approach to combine predictions from 4 
other public databases, while the latter uses a decision tree classifier to organize results 
from 11 difference online sources.  
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1.5.3. Disease-Specific Prioritization Methods  
Sometimes  it  is  useful  to  revisit  GWAS  data  by  limiting  one’s  search  space  to  a  
select number of target regions that are known to be influential to the phenotype of 
interest(Cantor, Lange, and Sinsheimer).  A recent re-analysis of GWAS data, after 
performing a set of initial filtering steps based on a priori knowledge, led to novel 
associations for researchers studying variations in human metabolic traits(Dharuri et al.).  
To create a prioritized list of SNPs to query, the researchers first interrogated the KEGG 
database for all pathways relevant to the particular metabolic process of interest, then 
extracted the SNPs in the original GWAS(Illig et al.) falling within +50kb these genes. 
While ultimately this approach was successful in identifying novel genetic risk loci, a 
downside to candidate gene queries of GWAS data is that the researcher is unable to 
discover novel biological insights beyond the known pathways of interest.  
In contrast, comparing GWAS data from different phenotypes may allow for the 
discovery of novel insights into the shared mechanisms of two related diseases. For 
example, we performed a gene-based focused inquiry of GWAS data to test the 
hypothesis  that  Alzheimer’s  Disease  (AD)  susceptibility  loci  are  also  associated  with  risk 
for Age-related Macular Degeneration (AMD)(M. W. Logue et al.).  The rationale behind 
this study stems from the observation that AD and AMD share many common molecular 
mechanisms in their disease progression and genetic risk factors, and that late stage AMD 
has been associated with coincident AD(Klaver et al.).  This work not only yielded 
several novel AMD risk loci, but also provided further evidence that AMD and AD share 
genetic underpinnings.   
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1.6 Next Generation Sequencing 
1.6.1. Rare Variants  
There are several convincing arguments that the heritability remaining 
unexplained by GWAS may be found in rare variants with large effect sizes(Gibson, 
“Rare  and  Common  Variants:  Twenty  Arguments.”). Because GWAS methods focus on 
SNPs that occur at a frequency of at least 1% or greater, causal variants that are found at 
lower frequencies in the population are overlooked by these scans. There are two 
challenges in performing genetic association studies of novel rare variants.  The first is 
detection, and the solution demands technology with finer screening capabilities than 
SNP-chips (see Section 1.6.2). The second is sample size.  By their nature rare, variants 
are not found to be recurrent in many individuals, requiring a large number of samples to 
be screened in order to identify a sufficient number of variant positive subjects with 
which to perform a well-powered statistical test. Online databases such as the Exome 
Sequencing Project(Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), 
Seattle, WA) or the 1000genomes Database(Abecasis et al.), can assist researchers in 
determining just how rare their particular variants of interest are and consequently how 
large of replication cohort would be need for validation.  However, rather than blindly 
screen patients to look for rare variants with large effects, studies may employ 
recruitment strategies that enrich for variant carriers. For example some screens for rare 
variants focus on extreme phenotypes for a disease, operating under the assumption that 
the severity of the disease is caused in part by particularly deleterious and rare genetic 
variations. Another approach to rare variant discovery, explained in greater detail in 
16 
 
 
 
Chapter 3, is to use family-based data to identify highly penetrant variations that uniquely 
explain heritability in certain pedigrees. 
1.6.2. Whole Exome and Whole Genome Sequencing  
Next-Generation Sequencing (NGS) technologies have the capability to quickly 
and accurately process millions of sequence reads in parallel. As such, they are rapidly 
becoming the primary tool for rare variant detection over previous targeted sequencing 
techniques, such as Sanger sequencing(Manolio et al.).  Unlike targeted sequencing 
approaches or exome-chip panels, both whole genome and whole exome sequencing 
NGS techniques (WGS and WES, respectively) allow for capture of rare variants across 
the entire genome, rather than only in pre-specified regions as with targeted sequencing. 
The disadvantage to targeted sequencing is that the selection of sequenced regions may 
be biased by incomplete knowledge of the disease etiology.  Alternatively, WGS covers 
the entire genome at a typical read depth of 30x coverage, while WES focuses only on 
the protein coding regions of the genome (or exons) and has an average read depth of 80-
100x coverage.  Each approach comes with its own advantages and challenges.  While 
WGS provides a more complete picture of the genome, the size of the files used to store 
the information is prohibitively large to allow for easy and affordable data transfer and 
storage.  WES offers a more efficient summary of the protein coding regions of the 
genome, which most analyses tend to focus on, however it does not allow for detection of 
large translocation events and/or regulatory variants that exist in introns and the 
intergenic regions of the genome.  
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1.6.3 Analysis Considerations of NGS Date 
As NGS technology becomes increasingly affordable for large-scale analyses, this 
technology offers much promise to shed light on the missing heritability problem of 
GWA data.  However, analysis of NGS data is not trivial.  Analysis of NGS data requires 
careful quality control protocols to protect against chasing spurious findings (see Chapter 
3).  Additionally, the frequency of rare variants is not conducive to detecting risk 
associations via single-variant analysis methods commonly applied to SNP-chip data.  In 
light of this fact, increased attention has been focused on aggregation techniques that 
measure the total gene-burden of rare variants in an individual and have greater power to 
detect novel gene-based associations.  However, as discussed in Section 1.5.2, not all 
variants have the same effect on protein function. Therefore, effective gene-burden tests 
will have to also incorporate biological knowledge to accurately score the severity of any 
particular variant.  Finally, NGS screens do not overcome the multiple-testing problem 
that is inherent in agnostic analyses.  Therefore, similar to analysis of GWAS data, 
judicious prioritization methods are needed for analysis NGS data.  
1.7 Discussion 
1.7.1. Lessons Learned 
Progress in explaining the full picture of the genetic influence on common human 
diseases has been slower than first anticipated. The effect sizes of many of the newly 
discovered genetic risk factors are either too low to be individually useful for predicting 
the risk of disease, or so infrequent that they account for risk in only a small portion of 
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the population. In hindsight, the CDCV hypothesis which spurred so much enthusiasm 
for GWAS, was in many ways at odds with classical population genetics theory which 
suggest that selective pressures will gradually encourage a reduction of large effect risk 
variants in the population(Manolio et al.; Khoury et al.). Still, the challenges of detecting 
rare and weak effect variants are not insurmountable. Patient enrollment for NGS studies 
of complex diseases continues to grow and new methods, such as those described in 
Chapters 2 and 3 of this dissertation, have promise to increase discovery of novel risk 
variants in GWAS and NGS datasets.  
Moreover, regardless of the pace at which the missing heritability of complex 
disease is being uncovered it is important to recognize how each new finding provided by 
GWA studies, no matter how small or rare, advances our understanding of human disease.  
Our ever-growing list of genetic risk factors continues to offer important clues to 
researchers seeking to piece together the molecular mechanisms of disease. To aid in this 
endeavor, statistical tools are being developed to decipher broader pathway associations 
from known risk variants(Yaspan et al.; Wang, Li, and Bucan). Furthermore, progress in 
unraveling the genetic underpinnings of disease has allowed clinicians to offer more 
effective therapies tailored to the specific genetic profiles of their patients(Wigle). Thus, 
even at this decidedly incomplete stage, findings from GWAS and other genetic 
experiments are still greatly influencing the way in which we understand human health, 
and pointing the way to new insights and new therapies in the future.  
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2. Distilled Sensing Applied to GWAS Data 
2.1. Introduction 
2.1.1. Motivation 
Although SNP-chip technology allows for assays of up to 2 million SNPs per 
sample, the statistical significance threshold after correcting for the number of 
independent tests is difficult to exceed.  Genome-wide association studies (GWAS) have 
yet to reveal the majority of the underlying genetic risk factors for common heritable 
diseases.  One explanation for missing heritability is that many of the undiscovered 
variants contributing to the risk of common diseases have relatively weak effects (OR < 
1.5). This scenario poses a problem for contemporary GWAS and meta-analyses.  Even 
with cumulative samples sizes totaling tens of thousands of case and control subjects, 
most GWA studies lack sufficient power to identify weak-effect loci given the stringent 
significance threshold inherent in agnostic testing of the genome. Hence, there is a strong 
need for new analytical methods to identify weak-effect genetic variants for common 
diseases.  The adaptive sampling technique, known as Distilled Sensing (DS), was 
developed to solve the sparse/weak signal detection problem. Our implementation of DS 
for GWAS data utilizes a portion of the total sample to eliminate regions of the genome 
where there is no evidence of genetic association, and then applies traditional association 
tests to a substantially reduced number of variants using the remaining sample.       
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2.1.2. Contemporary Prioritization Methods 
One of the underlying assumptions of GWAS is that most associated SNPs are in 
high linkage disequilibrium (LD) with the true causal variants for a particular disorder.  
Thus, even when an individual SNP achieves genome-wide significance (p < 5×10-8) and 
is replicated in a follow up genotyping experiment, there is a need for additional 
bioinformatic analysis to determine the location (within the boundaries of in peak  SNP’s 
LD block) of the causal variant. Once this is established, additional functional analysis is 
required to determine which gene (or genes) the causal variant is affecting and thereby 
influencing phenotype.  Given that replication is always required to have confidence in 
the veracity of genetic associations, there is a high demand for tools for assisting in 
selecting loci to replicate(Cantor, Lange, and Sinsheimer). In this chapter we propose a 
novel method of applying a Distilled Sensing (DS) algorithm to GWAS data to increase 
power of detecting weak effect loci when combining data from a series of GWAS data 
sets.   
Several methods have been proposed regarding how to prioritize results from 
GWAS. Pathway-based analysis methods,  for example, attempt to identify canonical 
gene-sets that are enriched for associated SNPs identified by GWAS.(Yaspan et al.; 
Wang, Li, and Bucan; Holmans et al.; Rossin et al.).  While these approaches can provide 
insights into the biological mechanisms contributing to development of disease, they are 
often biased towards prioritizing more frequently studied pathways (such as cancer 
signaling pathways). Furthermore, there is no agreement on a standard procedure for 
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annotating SNPs to genes and other functional elements, which is a critical initial step of 
any pathway analysis technique (Cantor, Lange, and Sinsheimer; Wang et al.).  
Rather than prioritize data using gene set annotations, which ignore large swaths 
of SNPs in intergenic regions, several other methods have been proposed to employ 
region-based tests that ascribe significant associations to specific DNA segments. One 
method for identifying regions of association is the moving-window scan whereby a 
cumulative significance value is calculated for a predetermined number of adjacent SNPs 
at regular intervals(Cheng et al.). One limitation of this approach is that moving-window 
scans do not take into account LD structure across the genome nor adjust for the variable 
density of SNPs within windows across the genome.  Instead, one must arbitrarily 
predetermine the size of the scan window.  
2.2. Adaptive Sampling 
2.2.1. Basic Principles 
One of the key obstacles in contemporarily scaled GWAS is that multiple testing 
correction present a huge burden which hinders the detection of weak-effect loci. This 
obstacle is inherent when studying any high dimensional data set, particularly when the 
number of features one could possibly test (in this case the number of independent SNPs) 
is orders of magnitude larger than the number of samples one has for testing. Furthermore, 
discovering risk loci for human disease from GWAS data represents a sparse signal 
recovery problem, as the number of risk loci researchers expect to be associated with a 
particular trait is significantly smaller than the total feature space one is searching. In 
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other words, we expect that the vast majority of SNPs in the genome are probably not 
associated with any one specific trait/disease.  Fortunately the challenge of sparse signal 
recovery has been well studied in the field of image reconstruction, and it is in drawing 
upon the experience of information theorists that geneticists can make immediate gains in 
detection of risk loci from GWAS data, as presented in this dissertation.   
Shental et al (2010) achieved superior detection of rare alleles in large population 
sequencing experiments by applying compressed sensing (CS) strategies to sequencing 
pipelines(Shental, Amir, and Zuk). Prior to applications in genetics, CS theory was 
successfully adapted to problems in magnet resonance imaging, single-pixel cameras and 
geophysics.  The general theory behind CS is to leverage the sparseness of a vector of 
known length (n) to represent the vector using a new set of k linear measurements, where 
k << n(Montefusco, Lazzaro, and Papi).  In many ways, this approach is similar to 
principle component analysis (PCA), which has been used to study population 
stratification in GWA studies(Freedman et al.), however PCA techniques do not assume 
signals are sparse nor attempt to leverage sparseness to resolve signal.     
2.2.2. The Promise of Distilled Sensing for GWAS 
Distilled Sensing (DS) is a new technique first proposed by Haupt et al for 
detecting signals from sparse data sets(Haupt, Castro, and Nowak). The general principle 
of this method is to iteratively remove areas with weak evidence for an association signal 
and thereby reduce the search space in later stages where one attempts to resolve the 
signal using an increasingly more sensitive screen.  Previously, this approach has been 
applied successfully in the fields of deep space photography and image resolution(Haupt, 
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Castro, and Nowak). Furthermore, DS has shown to be a superior resolution technique 
compared to standard meta-analysis approaches for image recovery in detecting the real 
underlying signal within a series of multiple noisy images(Haupt, Castro, and Nowak). 
DS resolution strategies have three distinct stages.  First is a focusing step in which a 
relatively low-resolution screen is applied to the existing search space in an effort to 
broadly characterize the amount of signal in various local domains.  In a subsequent 
trimming step, regions from the focusing step lacking sufficient evidence for signal are 
excluded from further consideration.  Finally, after any number of rounds of focusing and 
trimming, there is a sensing step which entails analyzing the surviving feature space with 
a scan that has as high (and typically higher) a resolution power as the previous focusing 
steps’  to finally determine the location and magnitude of the signal.  Notably, DS 
emphasizes identifying the location of a signal at the expense of characterizing the 
signal’s  magnitude, which is estimated in the sensing step using only a portion of the data. 
In essence, the DS method prioritizes detection of the coordinates of a sparse signal over 
precise estimation of the strength of the signal.  This method is consistent with the 
GWAS approach as replication is essential for both validation and improving estimates of 
the effect size.  
However, the potential for DS to increase discovery in GWAS data is dependent 
on a methodology for implementing each stage of DS analysis to these datasets. For this 
purpose, we developed the GRIDS method (Genome Reduction by Iterative Distilled 
Sensing) which uses a Likelihood Ratio Test (LRT) to test simultaneously all SNPs in a 
defined LD block in the focusing step and then applies a quantile-based threshold to these 
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regional scores in the trimming step. Finally, GRIDS uses a standard single SNP 
regression analysis in the sensing step to test the markers in the surviving regions from 
step two (see Figure 2). Our results using both simulated and real data suggest that this 
approach improves the ability to detect weak-effect loci over standard meta-analysis 
techniques in many situations.   
Figure 2: GRIDS Pseudo-Code 
 
Genome	  Reduction	  by	  Distilled	  Sensing	  (GRIDS) 
 
Guiding	  Principe:	  Given	  a	  collection	  of	  noisy	  data	  it	  is	  easier	  to	  
determine	  where	  the	  signal	  ISN’T	  rather	  than	  find	  where	  it	  IS.	   
 
Procedure:	   
Step	  1:	  Determine	  the	  proportion	  of	  data	  to	  be	  budgeted	  for	  the	  
data	  into	  focusing	  and	  sensing	  stages	  of	  the	  analysis.	   
 
Step	  2:	  Group	  clusters	  of	  SNPs	  into	  regional	  LD	  blocks	  determined	  
by	  the	  appropriate	  HapMap	  reference	  panel.	   
 
Step	  3:	  Apply	  low	  a	  resolution	  Likelihood	  Ratio	  Test	  (LRT)	  to	  SNPs	  
within	  LD	  blocks	  to	  determine	  which	  regions	  show	  little	  
evidence	  of	  harboring	  SNPs	  associated	  with	  risk	  of	  disease.	  	   
 
Step	  4:	  Remove	  regions	  with	  the	  least	  evidence	  of	  association	  from	  
the	  search	  space. 
 
Step	  5:	  Apply	  finer	  resolution	  SNP-based	  association	  test	  to	  
remaining	  data	  to	  only	  those	  SNPs	  in	  regions	  surviving	  data	  
trimming	  in	  Step	  4. 
 
Step	  6:	  Determine	  which	  loci	  show	  significant	  evidence	  for	  
association	  with	  disease	  after	  correcting	  for	  appropriate	  
multiple	  testing	  burden	  in	  trimmed	  search	  space.	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2.3. Methods 
2.3.1. Defining Regions Based on LD 
In developing GRIDS, we first had to define regional blocks of the genome on 
which to apply the LRT.  In other fields using DS techniques, a uniform partitioning of 
the search space is a sufficient approach for defining domains to be tested in the initial 
focusing step. However, because of the correlation structure among SNPs in discrete 
segments (i.e., regions of LD) across the genome, defining domains for the focusing step 
must incorporate the underlying LD structure to partition the genome based on the 
coordinates of existing haplotype blocks.  While several annotations exist and for 
defining LD blocks, we used the annotations defined by coordinates derived by Pallejà et 
al and implemented in their DistiLD database as the heuristics of their annotation 
procedure ensure unique mapping of SNPs to LD blocks(Pallejà et al.). Haplotype blocks 
were defined by calculating the average LD at each point across the genome using both 
course (+60kb) and fine window (+5kb) scan. Caucasian sample genomes available from 
the International HapMap Project(International HapMap Consortium) were used as the 
reference set for estimating LD.  While this reference is appropriate for many analyses 
including the AMD data set presented in Section 2.5, alternative sets of coordinates 
should be selected to define initial focusing domains when applying GRIDS to non-
Caucasian data sets if such annotations exist.   
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2.3.2. Allocating Data Resources  
The selection of the portion of data to include in the focusing (versus sensing) 
group is discussed in greater detail in Section 2.4.2. One practical consideration which 
greatly influences this decision is that applying the LRT requires access to the raw 
genotype data or imputation results from the original GWAS. Meanwhile, only the 
summary statistics from the original GWAS are needed for the subsequent sensing step. 
This caveat of the focusing step may predetermine how datasets are apportioned in these 
two steps. Based on simulation data, we observed that the optimum proportion of the data 
to budget in the focusing step, F, decreases with the size of the total number of samples, 
N, available across all studies as described in the following equation.   
𝐹 = 𝛽ி𝑁 + 𝐹଴   (2.1) 
where βF = -0.095, SE(βF) = 0.023, F0 = 0.10, and SE(F0) = 0.01 with N representing 
each 100,000 samples in the data set or fraction there of. The derivation of this equation 
is explained in greater detail in Section 2.4.  However, it is worth noting that while this 
equation describes the relationship between the optimum choice of F relative to N, our 
simulation experiments revealed that the success of the GRIDS algorithm over standard 
meta-analysis was rather robust to the selection of the F.  In general, successful design 
strategies used 5%-20% of the data in the focusing step with the reminder in the sensing 
step. In practical terms, we recommend that the user of the GRIDS algorithm select a data 
set where the total number of samples comes as close to the recommended F×N as 
possible, but in general anything within 5-10% of this ideal fraction should perform 
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comparably well.  Also, implicit in this linear relationship between F and N is both an 
upper and lower bound on the total number of samples where distilled sensing as 
implemented in GRIDS robustly outperforms standard meta-analysis techniques.  We 
found in our simulation data that power for detecting association using GRIDS is 
equivalent to or below that of traditional meta-analysis for data sets with a combined total 
number of samples less than 2,000 individuals or above 80,000 individuals.  Therefore, 
researchers with discovery GWAS data sets outside this range would be advised to use 
other techniques to search for weak effect variants.   
2.3.3. Applying the LRT to SNP Data 
As mentioned in Section 1.3.3, regression methods are popular for modeling the 
risk associated with having one or more copies of a particular allele.  Since many GWA 
analyses compare the relative frequency of alleles between cases and controls, let us first 
consider a standard logistic model for modeling association.   
𝑙𝑜𝑔𝑖𝑡(𝑝௜) = ln ൬
𝑝௜
1 − 𝑝௜
൰ = 𝛽଴ + 𝛽௜𝑥௜              (2.2) 
 where pi is the probability of having the disease given one has the xith genotype, which 
represents the genotype of the ith SNP.  Typically, xi is coded additively but the general 
model is the same for all genotype-coding schema (see Table 1). In this case we are 
testing the null hypothesis that βi = 0.  If there is sufficient evidence to reject H0, then the 
SNP is significantly associated with the disease. Because of the number of independent 
logistic models that are run in a GWAS, the Bonferroni multiple testing correction 
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demands that the threshold  needed  to  reject  the  null  be  set  at  α  < 5×10-8 (see Section 1.3.2. 
Multiple testing burden). 
However, in the focusing step of GRIDS, each each SNP is not tested individually. 
Instead, for all the k SNPs that are contained in a particular LD block,  the  entire  region’s  
influence on disease risk is modeled as follows: 
𝑙𝑜𝑔𝑖𝑡(𝑝) = 𝛽଴ + 𝛽ଵ𝑥ଵ + 𝛽ଶ𝑥ଶ + 𝛽ଷ𝑥ଷ + ⋯𝛽௞𝑥௞  (2.3) 
This model tests whether any of the SNPs in this region (either individually or as a group) 
suggest evidence of association with phenotype. For binary data, the significance of the 
model is evaluated using the LRT as explained in greater detail below.  However, for 
continuous phenotypes, a linear regression model would be used instead and statistical 
significance would be evaluated employing an F-test in lieu of the LRT.  
When applied to regression models, the LRT compares the proportion of variance 
explained between two models, a restricted model and an unrestricted model, and tests 
whether the unrestricted model explains significantly more variance than that accounted 
for by the restricted model.  Since many GWAS use binary classifications for case versus 
control phenotypes, for illustrative purposes let us assume that we are fitting a logistic 
regression model to our regional SNP data.  We may then write our restricted (modr) and 
unrestricted (modu) models as,  
𝑚𝑜𝑑௥: 𝑙𝑜𝑔𝑖𝑡(𝑝) =   𝛽଴                                                                            
𝑚𝑜𝑑௨: 𝑙𝑜𝑔𝑖𝑡(𝑝) =   𝛽଴ + 𝛽ଵ𝑥ଵ + … + 𝛽௞𝑥௞
          (2.4) 
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The difference of the deviances of these two models follows a chi-squared distribution 
with k degrees of freedom, where k is the number of additional covariates in modu that are 
not represented in modr.  
𝐷𝑒𝑣(mod௥) − 𝐷𝑒𝑣(mod௨)   ∼   𝜒ଶ      with  df = 𝑘        (2.5)    
This allows us to test the following null and alternative hypothesis,  
𝐻௢:  𝛽ଵ = 𝛽ଶ = 𝛽ଷ = ⋯ = 𝛽௞ = 0
𝐻ଵ:  ∃𝑖 ∈ {1,2,3, … 𝑘}: 𝛽௜ ≠ 0
      (2.6) 
which is the same desired hypothesis represented in equation 2.3.  Hence, the LRT 
provides a means to test each LD block for regional association with disease.  Therefore, 
instead of testing over 2 million SNPs, in the initial stage of GRIDS, only 36,925 regions 
are tested before subsequent trimming, assuming that the search space is restricted to the 
non-sex chromosomes (autosomes) only in Caucasians.  
2.3.4. Quantile Based Trimming 
The selection of a trimming threshold is a critical step in the DS algorithm, 
particularly as it is implemented in GRIDS.  The choosing the statistical criteria for 
selecting loci from the discovery GWAS for replication is often problematic. While it is 
desirable to limit the number of candidate SNPs (or regions) to minimize both the cost of 
replication and the multiple-testing burden in subsequent validation experiments, it is also 
important to reduce the risk of false negatives due to imposing overly conservative 
thresholds for follow-up analysis.  
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Extensive simulations were performed, testing over 500,000 initial conditions to 
determine the most appropriate quantile-based threshold for trimming genomic regions 
from the search space given the total sample size of the dataset.  This threshold can be 
described by the function: 
𝑞 = 𝛽௤𝑁 + 𝑞଴ (2.7) 
where βq = 0.18, SE(βq) = 0.083, q0 = 0.20, and SE(q0) = 0.036 with N representing each 
100,000 samples in the data set.  Here q denotes the quantile-based threshold defining the 
rank of the regions that are forwarded to the sensing step and N is the total number of 
individuals (cases and controls) with available GWAS data. The simulation and modeling 
procedures used to arrive at this equation are described in greater detail in Section 2.4.3.  
2.3.5. Sensing with Appropriate Multiple Testing Correction 
After  trimming  1  −  q percent of the genome, in the remaining portion of the 
sample budget allocated for sensing we will return to a single SNP regression based-
approach to testing for association, but now only testing SNPs existing in the portion of 
feature space surviving from the previous step.  Because we are no longer testing 1 
million different independent regions of the genome, we adjust our genome-wide 
significance  threshold,  αg = 5×10-8 as follows.   
𝛼ீோூ஽ௌ = 𝛼௚ ⋅
ଵ
௤
   (2.8) 
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This threshold is a result of performing a Bonferroni multiple testing correction for the 
estimated 1,000,000 × q independent tests perform in our sensing step of GRIDS (where 
q < 1).  
2.4. Simulation Results 
2.4.1. Generating Simulated Data 
To study the conditions where the GRIDS algorithm could be successfully applied 
and improve the power to detect effect variants from GWAS data, we analyzed results 
from over 500,000 simulated data sets.  The computer-generated GWAS data was created 
using the GWAsimulator software which allows for rapid generation of multiple genomic 
regions while preserving the LD structure of the genome as estimated from a selected set 
of phased reference genomes provided by the user(Li and Li). As reference dataset for 
these simulations, Caucasian phased genome samples from the HapMap reference panel 
were used(International HapMap Consortium).  If a more appropriate reference set of 
human genomes exists for the population of interest, it is recommended that one 
recalculate the focusing function (Equation 2.1) and trimming function (Equation 2.7) 
with such a panel as described below. Throughout this section, we compare the results of 
GRIDS to standard meta-analysis output.  To generate the standard meta-analysis results, 
the summary statistics of the individual computer-generated GWAS data sets were 
combined using the inverse variance method for meta-analysis as implemented in 
METAL(Willer, Li, and Abecasis). 
32 
 
 
 
2.4.2. Selecting the Focusing/Sensing Data Partition 
Our simulation work addressed two important questions, namely, given the total 
number of samples with SNP chip data, what is the best choice of F and the best choice 
of q to select when running GRIDS?  In each of these cases, the total number of samples, 
N, is modeled as the independent variable given that typically this number is already 
determined before the analysis stage of a GWAS or GWAS meta-analysis experiment.   
To determine the relationship between F and N, we simulated over 500,000 
conditions varying all of the relevant parameters to the GRIDS algorithm in an effort to 
find the ideal partitioning of the total number of samples that resulted in the greatest 
number of scenarios where GRIDS would outperform traditional meta-analysis (see 
Figure 3).  For each choice of simulated N, we found the corresponding best partitioning 
(F) that created the greatest opportunity for GRIDS to outperform standard meta-analysis 
procedures.  To quantify the magnitude of the potential for improvement over meta-
analysis, we varied the effect size of the simulated risk variants and threshold for 
trimming across the plane in our feature space that is defined by fixing N and F (see 
Figure 3).  By comparing the number of simulated loci detected by of GRIDS, LDS, to the 
number of loci detected by METAL, Lmeta, over thousands of conditions in this plane, one 
can define a surface of initial conditions that we refer to as the success domain (SDS) 
where the DS methods outperforms meta-analysis as follows: 
𝑆஽ௌ(𝐹, 𝑁, 𝐸, 𝑞) =    ൜
1,                       𝐿஽ௌ(𝐹, 𝑁, 𝐸, 𝑞) > 𝐿௠௘௧௔(𝐹, 𝑁, 𝐸, 𝑞)
0,                         𝐿஽ௌ(𝐹, 𝑁, 𝐸, 𝑞) ≤ 𝐿௠௘௧௔(𝐹, 𝑁, 𝐸, 𝑞)
           (2.9) 
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where LDS(F,N,E,q) and Lmeta(F,N,E,q) are both functions of the 4 relevant initial 
conditions for  GRIDS that we are testing – namely, the proportion of data in the focusing 
budget, number of total samples in the simulated experiment, effect size of risk loci, and 
trimming parameter, respectively. Here the boundaries of the success domain encompass 
all initial conditions on the E-q plane where SDS = 1. Then for each N, we can select the 
corresponding best observed budgeting of data, 𝐹෠, which resulted in the success domain 
with the largest area, calculated as follows: 
𝐹෠(𝑁) = 𝑎𝑟𝑔𝑚𝑎𝑥(∑ ∑ 𝑆஽ௌ(𝐹, 𝑁, 𝐸, 𝑞)௤ா )
𝐹                                                          
            (2.10) 
In equation 2.10, N is fixed and the values of E and q are allowed to vary through 
a reasonable range of initial values.  Since the points defining the success domain are 
discrete, we take the summation of SDS of all tested values of E and q. For simulated 
variant effect size, E, a range of weak effect parameters from OR=1.01 to OR=1.3 were 
tested.  Meanwhile, in this simulation step the range of q was allowed to vary from 0.1 to 
0.9.  Using a standard linear regression model (see Table 2) we found that the final 
relationship between N and  𝐹෠ is best represented as follows.  
𝐹෠ = 𝛽ி𝑁 + 𝐹଴   (2.1) 
where βF = -0.095, SE(βF) = 0.023, F0 = 0.10, and SE(F0) = 0.01 with N representing 
each 100,000 samples in the data set. However, as Figure 5 shows, if we look not only at 
the optimum selection of F but instead the top 3 choices of budget partitioning that led to 
the most simulations where GRIDS out performed meta-analysis, then we see that the 
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selection of F is actually rather robust.  Therefore, in practice, choosing an F within a 
window +5% of the 𝐹෠ represented in Equation 2.1 (or +10% for N > 35,000) should 
allow comparable improvement in detection of weak-effect variants relative to an 
implementation of GRIDS using the optimum choice of 𝐹෠. 
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Figure 3: Parameter Space Sectioned by Focusing Budget 
 
Figure 3 shows the success domains, or conditions where GRIDS exhibits superior 
detection strength over meta-analyzing all of the data, at various choices of F, the 
simulated focusing budget. In this example, the total number of simulated case and 
control samples has been fixed at 5000 simulated individuals (2500 cases and 2500 
controls) per each simulated region. The orange domain (F =10%) represents the choices 
of the trimming threshold, q, and corresponding effect of variant(s), E, where GRIDS has 
greater detection power over meta-analysis. In this particular example, this 10% 
partitioning had the largest success domain in the E-q projection of the parameter space, 
and therefore represents the most robust choice of budgeting for this set of simulations.  
However, it is worth noting the that red and yellow planes (F = 5% and 15% 
respectively) have areas of similar magnitude to the optimal plane, suggesting the choice 
of what fraction of the data to assign to the focusing step, F, is itself robust at this 
particular number of total samples.  
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Table 2: Modeling F and q from N 
Model Coefficient  Estimate (SE) p-value  
F = βFN + F0 βF -0.095 (0.023) 2.1×10-3 
F0 0.099 (0.01) 1.7×10-6 
  
  
  
q = βqN + q0 βq 0.18 (0.083) 5.2×10
-2 
q0 0.20 (0.036) 2.7×10-4 
        
 
Table 2 shows the parameters for the linear models describing the relationship between 
the optimum choice of a focusing budget, F, and optimum choice of a quantile trimming 
threshold, q, based on the total number of 100,000 samples (or fraction there of) available 
for study, N.  Coefficient estimates were derived using the lm() function as implemented 
in R and available the CRAN stats package.  
37 
 
 
 
Figure 4: Plotting optimum parameter choices from simulation analysis 
 
Figure 4A shows the best identified choice of F over from our GRIDS simulations per 
each choice total N samples that were generated. The red line indicates the linear fit of 
Equation 2.1 (F = βFN + F0) described in Table 2 and elsewhere in the text.  At each top 
choice of F, we also found the best choice of quantile trimming threshold, q, as seen in 
Figure 4B.  The blue line here indicates the linear fit of Equation 2.7 (q = βqN + q0) 
described in Table 2 and elsewhere in the text. 
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Figure 5: Range of top most robust choices of F given N 
 
Figure 5 shows the weighted average of the top three optimum choices (in red) of 
focusing budget, F, given several choices of total sample, N, in our simulations. In the 
graph the black horizontal bars show the full range of focusing conditions that composed 
the top three partitions.   
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2.4.3. Selection of the Trimming Parameter 
The selection of the trimming parameter, q, was calculated from the largest 
success domain for each simulated choice of N and corresponding observed 𝐹෠ (see 
Section 2.4.2. ). After fixing N and 𝐹෠, we determine the optimum choice of the trimming 
threshold, 𝑞ො, by first projecting the relative increased power of GRIDS over meta-
analysis for every point where SDS=1 on the selected success domain. Here we define the 
relative increase in power, ΔP, as  
Δ𝑃(𝑁, 𝐹෠, 𝐸, 𝑞) = ௅ವೄ(ே,ி
෠,ா,௤)ି௅೘೐೟ೌ(ே,ி෠,ா,௤)
ே  ೞ೔೘(ே,ி෠,ா,௤)
    (2.11) 
where Nsim(N,F,E,q) represents the number of simulations run using the corresponding 
initial conditions.  This value may vary from point to point in the parameter space, 
however generally speaking Nsim(N,F,E,q) > 100. As shown in Figure 6 there is a good 
deal  of  variability  of  ΔP across the feature space projection, highlighting the importance 
of selecting an appropriate trimming parameter value. Figure 7 demonstrates how the 
optimum 𝑞ො for a given N was selected, namely by showing several cross-sections of the 
3-dimensional projection in Figure 6. In general, for each selection of q, the magnitude of 
ΔP varies non-linearly with E, assuming 𝐹෠and N are fixed.  Since, in practice, we cannot 
control the true effect size of the novel risk variants we wish to discover, our goal is to 
select the best choice of q that maximizes our ΔP over the cumulative range of weak 
effect variants targeted.  
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 In other words, for a fixed N and 𝐹෠, we define 𝑞ො as follows:   
𝑞ො(𝑁) = 𝑎𝑟𝑔𝑚𝑎𝑥(∑ Δ𝑃൫𝐹෠, 𝑁, 𝐸, 𝑞൯ா )
𝑞                                                          
            (2.12) 
As before, our tested values of E, range from OR=1.01 to OR=1.3.  Repeating this 
procedure for finding 𝑞ො over all of the simulated choices of N that we generated, then we 
can determine the relationship of q to N to as: 
𝑞ො = 𝛽௤𝑁 + 𝑞଴     (2.7) 
where βq = 0.18, SE(βq) = 0.083, q0 = 0.20, and SE(q0) = 0.036 with N representing each 
100,000 samples in the data set.  Again, as 𝐹෠ is already with the predetermined choice of 
N, 𝑞ො is only a function of the total number of samples one has for analysis. While Figure 
6 shows that cumulative sum of ΔP across E is somewhat robust to our choice of q, since 
the selection of trimming threshold is not dependent on external factors (such as the size 
of available data sets), we recommend that researchers using GRIDS in subsequent 
analyses select a trimming threshold within the nearest 1% of the calculated 𝑞ො quantile 
threshold.  
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Figure 6: Projection of power gained over effect size and trimming threshold 
 
In Figure 6, the relative increase in power, ΔP (see Equation 2.9), over standard meta-
analysis is represented on the z-axis.  The x and y axes represent the effect size of the 
seeded disease variant and the choice of trimming threshold hold, respectively.  In this 
example the total size of the simulated data set is fixed at 10,000 individuals (5000 cases 
and 5000 controls).    
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Figure 7: Cross-sections  of  the  ΔP projections 
 
Figure 7 shows vertical cross sections of the parameter space plotted in Figure 6.  The red, 
blue and green lines represent 2%, 5%, and 7% relative gains of power observed when 
the results from GRIDS is compared to the results of meta-analyzing the entire data set.  
In this case, where N=10,000, the optimum choice of the trimming parameter would be 
𝑞ො=0.135.   
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2.5. Distilled Sensing Algorithm Applied to AMD GWAS 
2.5.1. Introduction 
As an initial real world test-case, data were selected from a recently published 
GWAS of age-related macular degeneration (AMD)(Fritsche et al.). In addition to 
validating several previously discovered genetic risk loci for the debilitating eye disease, 
this large collaborative effort by the AMD Gene Consortium also discovered seven novel 
associations that were subsequently verified via replication analysis. As described below, 
GWAS has contributed greatly to current knowledge about genetic factors for AMD. The 
following sections describe the application of GRIDS to AMD GWAS data. 
2.5.2. Genetics of Age-related Macular Degeneration 
AMD is the most common cause of blindness and vision loss among individuals 
over 60 years of age(Congdon et al.).  Affecting primarily the central field of vision, the 
advanced form of the disease is classified as one of two phenotypes: dry or wet AMD.  
The more common dry form accounts for roughly 85% to 90% of AMD cases.  
Sometimes this form of the disease will progress to the acute wet form (i.e. neovascular), 
which is responsible for the majority of blindness in persons with AMD. However, it 
should be noted that while dry AMD often precedes wet AMD, it is not a necessary 
precursor stage for the development of the neovascular form of the disease.  
GWA studies have yielded several established common genetic risk factors for 
the disease(Manolio et al.).  The first two gene regions identified harboring as significant 
risk loci for AMD were CFH and ARMS2/HTRA1. These AMD risk loci have been 
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replicated across multiple populations and established as having large effect sizes (OR > 
2.5)(Edwards et al.; Jakobsdottir et al.; R. J. Klein et al.; Rivera et al.).  The discovery of 
the link between AMD and CFH, which encodes for the complement factor H protein, 
initiated other genetic investigations linking aberrations in the complement pathway to 
AMD risk.  From these candidate gene studies, several other AMD risk genes were found 
including C2/CFB, C3, and CFI, however the effect sizes of these risk loci were observed 
to be much smaller (OR < 2)(Gold et al.; J. B. Maller et al.; Yates et al.; Fagerness et al.). 
Additionally, many other loci of modest effect have been discovered (and replicated) via 
GWAS methodologies(W. Chen et al.; Fritsche et al.; Yu et al.). A recent high-powered 
meta-analysis performed by the AMDGene Consortium identified 19 independent loci 
associated with AMD risk from a two stage discovery-replication analysis experiment 
collectively pooling data from over 77,000 samples(Fritsche et al.) (see Table 3). Several 
of these loci, including CFH, C3, LIPC, and DDR1, have multiple risk variants that 
independently contribute to disease risk(Fritsche et al.; Gold et al.; M. Li et al.; J. Maller 
et al.). Beyond genetics and age, other risk factors for AMD include smoking(R. Klein et 
al.), hypertension and/or high blood pressure(Hyman  et  al.;;  “Risk  Factors”;;  van  Leeuwen  
et al.) , and atherosclerosis(Casserly and Topol; van Leeuwen et al.).  
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Table 3: AMD risk variants found by GWAS 
SNP  Ch Position Nearby genes MAF p-value OR (95% CI) 
rs10490924 10 124.2 Mb ARMS2-HTRA1 0.3 4 × 10−540 2.76 (2.72–2.80) 
rs10737680 1 196.7 Mb CFH 0.64 1 × 10−434 2.43 (2.39–2.47) 
rs429608 6 31.9 Mb C2-CFB 0.86 4 × 10−89 1.74 (1.68–1.79) 
rs5749482 22 33.1 Mb TIMP3 0.74 2 × 10−26 1.31 (1.26–1.36) 
rs2230199 19 6.7 Mb C3 0.2 1 × 10−41 1.42 (1.37–1.47) 
rs4420638 19 45.4 Mb APOE 0.83 2 × 10−20 1.30 (1.24–1.36) 
rs1864163 16 57.0 Mb CETP 0.76 7 × 10−16 1.22 (1.17–1.27) 
rs13081855 3 99.5 Mb COL8A1-FILIP1L 0.1 4 × 10−13 1.23 (1.17–1.29) 
rs3130783 6 30.8 Mb IER3-DDR1 0.79 2 × 10−11 1.16 (1.11–1.20) 
rs13278062 8 23.1 Mb TNFRSF10A 0.48 3 × 10−15 1.15 (1.12–1.19) 
rs334353 9 101.9 Mb TGFBR1 0.73 3 × 10−11 1.13 (1.10–1.17) 
rs8135665 22 38.5 Mb SLC16A8 0.21 2 × 10−11 1.15 (1.11–1.19) 
rs943080 6 43.8 Mb VEGFA 0.51 9 × 10−16 1.15 (1.12–1.18) 
rs8017304 14 68.8 Mb RAD51B 0.61 9 × 10−11 1.11 (1.08–1.14) 
rs920915 15 58.7 Mb LIPC 0.48 3 × 10−11 1.13 (1.09–1.17) 
rs4698775 4 110.6 Mb CFI 0.31 7 × 10−11 1.14 (1.10–1.17) 
rs9542236 13 31.8 Mb B3GALTL 0.44 2 × 10−8 1.10 (1.07–1.14) 
rs6795735 3 64.7 Mb ADAMTS9 0.46 5 × 10−9 1.10 (1.07–1.14) 
rs3812111 6 116.4 Mb COL10A1 0.64 2 × 10−8 1.10 (1.07–1.14) 
All results reported are form the combined meta-analysis of both the discovery and 
replication analyses.  Details of these analyses and the data sets used in the meta-analysis 
can be found elsewhere(Fritsche et al.). Abbreviations used in this table include Ch = 
chromosome; MAF = minor allele frequency; OR = odds ratio; and CI = confidence 
interal.   
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2.5.3. Description of data in discovery meta-analysis 
In total, 14 different research centers contributed data to the discovery phase of 
the AMDGene Consortium experiment (see Table 4).  Minimal criteria for inclusion in 
this phase of the analysis were that samples must be genotyped on a validated SNP-chip 
platform and that at least 45 case samples (individuals with advanced AMD) and 45 age-
matched control samples be available for analysis.  Samples were genotyped on a variety 
of different platforms summarized in Table 5.  Each group submitted results from 
association tests of imputed data where the allelic dosages were computed with either 
MACH(Y. Li, C. J. Willer, et al.), IMPUTE(Marchini et al.), BEAGLE(Browning and 
Browning), or snpMatrix(Clayton and Leung) software packages using the HapMap2 
panels(International HapMap Consortium) as a reference genome. For most data sets, 
association tests were run under a logistic regression model using either PLINK(Purcell 
et al.), Mach2dat(Y. Li, C. Willer, et al.), ProbABEL(Aulchenko, Struchalin, and van 
Duijn), or snpMatrix(Clayton and Leung) software packages, though for one dataset 
containing related individuals the logistic model was run using the generalized estimating 
equations algorithm(Zeger and Liang) (GEE) as implemented in R. The analysis of each 
dataset adjusted for population stratification by either applying a genomic control 
correction and/or adjusting for principle components in the model.  Standard quality 
control measures were employed to remove low quality SNPs.  In general SNPs with 
minor allele frequencies (MAF) less than 0.01 were removed from analysis, though in 
some cases the MAF inclusion threshold was as high as 0.05.  Additionally, SNPs with 
low call rates (< 0.95) were removed before imputation.  After imputing each set using 
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the HapMap2 reference panels, SNP dosages with low imputation scores (R < 0.8) where 
removed prior to meta-analysis.    
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Table 4:AMD GWAS Contributing Studies 
  Cases Controls 
Studies N  %F %CNV %GA %Mixed N %F 
AMD-EU-JHU 963 63% 40% 43% 17% 4,262 52% 
BDF (India) 110 34% 90% 0% 10% 119 54% 
BMES 103 64% 47% 40% 14% 1,052 56% 
UK Cambridge/ 
Edinburgh 300k 150 57% 72% 18% 10% 601 46% 
UK Cambridge/ 
Edinburgh 550k 743 55% 65% 21% 14% 1,598 52% 
deCODE AMD 721 33% 27% 28% 45% 33,463 42% 
FAS/KORA 317 73% 46% 30% 24% 1,636 51% 
JAREDS 827 31% 100% 0% 0% 3,323 44% 
MEEI 71 52% 100% 0% 0% 76 62% 
Melbourne 49 63% 49% 43% 0% 49 55% 
Miami/Vanderbilt 867 63% 74% 17% 9% 689 56% 
MMAP 1,464 62% 54% 29% 17% 1,150 56% 
Rotterdam 192 60% 35% 42% 23% 1,887 57% 
Tufts/MGH 912 56% 73% 27% 0% 1,679 44% 
UCSD GA 161 61% 0% 100% 0% 260 76% 
Total 7,650 54% 60% 26% 14% 51,844 45% 
 
Table 4 gives the breakdown of samples contributed by each institution in the discovery 
phase of the AMDGene Consortium study. N Cases includes only cases with geographic 
atrophy (GA), choroidal neovascularization(CNV) or both (Mixed). N Controls gives the 
number of age-matched AMD-negative individuals screened each in the respective local 
study. %F indicates the percentage of female samples in each cohort.  
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Table 5: Genotype platforms and software packages used by cohorts 
Study Genotyping Method Genotyping Analysis Software 
Imputation 
Software 
AMD-EU-JHU 
Illumina HumanHap300 
BeadChips or Illumina 
Human610-Quad BeadChips 
MACH2DAT MACH v1.0 
BDF (India) Affymetrix 250K  Logistic regression on allele dosage using R MaCH v1.0 
BMES 
Illumina Human670-
QuadCustom chip (as part of 
WTCCC2) 
ProbABEL MACH v1.0.16 
UK Cambridge/ 
Edinburgh 300k 
Illumina Infinium 
HumanHap300K BeadChip R package snpStats 
R package 
snpStats 
UK Cambridge/ 
Edinburgh 550k 
Illumina Infinium 
HumanHap550v3 BeadChip R package snpStats 
R package 
snpStats 
deCODE AMD 
Illumina HumanHap300 or 
HumanHapCNV370 
BeadChips 
SNPTEST v2 IMPUTE v1 
FAS/KORA 
Affymetrix GeneChip 
Human Mapping 250k StyI 
Array 
SNPTEST v2.1.1 BEAGLE v3.1.0 
JAREDS 
Cases: Illumina 610-quad 
BeadChip; Ctrls: Illumina 
HumanHap550v3 BeadChip 
MACH2DAT MACH v1.0 
MEEI Affymetrix 6.0 GEE implemented in R MACH v1.0.16 
Melbourne Affymetrix 6.0 PLINK 1.04 MACH v1.0 
Miami/ 
Vanderbilt Affymetrix 1M 
Logistic regression as 
implemented in PLINK 
MACH 
v1.0.16 
MMAP Illumina HumanCNV370v1 MACH2DAT MACH v1.0 
Rotterdam Illumina Infinium II HumanHap550 MACH2QTL MACH v1.0 
Tufts/MGH Affymetrix 6.0 PLINK 1.07 BEAGLE 
UCSD GA 
Cases: Illumina 660-Quad 
v1A; Controls: Illumina 610-
Quad 
Java MACH v1.0.16 
Table 5 shows the choice of SNP-chip platform, genotyping software, and imputation 
software used by each cohort who contributed GWAS data to the discovery meta-analysis.  
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2.5.4. Methods: Applying GRIDS to AMD data sets 
 
Given the size of the AMD discovery cohort, the optimal data set in the focusing 
step would include about 12% of the cases (see Equation 2.1).  While this would suggest 
that the Tufts/MGH cohort would be the ideal candidate data set to use in our first stage 
of the analysis, we did not have access to the raw genotype data for this data set and 
therefore selected for the focusing step the Michigan/Mayo Clinic/AREDS/UPENN 
AMD data set (MMAP)(W. Chen et al.).  Fortunately, the total size of MMAP, which 
contains 18% of the cases in the discovery dataset, falls within 6% or the estimated 𝐹෠.  
As demonstrated in our simulated data analysis, GRIDS is rather robust to the choice of F, 
and this minimal difference between our selected F and calculated 𝐹෠ was expected to 
have little impact on the ability to detect weak-effect risk variants.   
In the original study, the AMDGene investigators analyzing the MMAP data 
adjusted for population stratification in their data set by including the first 3 principle 
components (PCs) for each sample as calculated using EIGENSTRAT(Price et al.).  The 
flexibility of the LRT also allows for correction of population stratification in a similar 
manner, by defining the restricted and unrestricted models as follows: 
𝑚𝑜𝑑௥: 𝑙𝑜𝑔𝑖𝑡(𝑝) =   𝛽଴ + 𝑝𝑐1 + 𝑝𝑐2 + 𝑝𝑐3                                                                            
𝑚𝑜𝑑௨: 𝑙𝑜𝑔𝑖𝑡(𝑝) =   𝛽଴ + 𝑝𝑐1 + 𝑝𝑐2 + 𝑝𝑐3 + 𝛽ଵ𝑥ଵ + … + 𝛽௞𝑥௞
          (2.12) 
where, pc1, pc2, and pc3 represent the first three principle components, respectively, and 
x1… xk represent the imputed dosages of the 1st through kth SNPs in a given LD block.  
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After applying the LRT to the 36,925 independent haplotype blocks defined for 
this (Caucasian) sample, the regional results from the LRT were rank-ordered and the top 
q of these regions were included in the proximal sensing step in GRIDS.  We used a 
trimming threshold defined by Equation 2.7 of 𝑞ො= 0.307.  Because the search space was 
then reduced to 30.7% of its original size, the statistical significance threshold in the 
sensing step was increased from the genome-wide threshold of 𝛼 = 5 × 10ି଼ to 
𝛼ீோூ஽ௌ = 1.63 × 10ି଻.  To perform the final sensing step in the GRIDS algorithm, the 
remaining 13 AMD GWAS data sets not included in the focusing step were meta-
analyzed using the METAL software package in a manner similar to the original 
discovery meta-analysis(Fritsche et al.).  SNPs in the surviving top 30.7% of regions 
were tested for association with AMD risk.   
To evaluate the performance of GRIDS relative to traditional meta-analysis 
practices, each approach was benchmarked by the number of loci passing the respective 
Bonferroni multiple testing correction p-value threshold after either methodology was 
applied to the discovery data sets used in the aforementioned AMD analysis.  Because 
including SNPs from other analyses of the same data set complicates the issue of how to 
appropriately adjust for the number of multiple tests performed, we focused only on the 
results of primary statistical model from this study, which employed a logistic regression 
model (unadjusted for age or gender) to test SNPs for association with advanced AMD 
(either GA, CNV, or both).     
52 
 
 
 
2.5.5. Results 
After applying GRIDS to the AMDGene discovery sample, 16 loci were 
identified as being significantly associated with risk for advanced AMD including two 
loci that previously did not achieve genome-wide significance via meta-analysis of the 
same data (see Table 6).  As a positive control, all loci that were previously detected by 
meta-analyzing the results of the primary statistical model in the AMD discovery cohorts 
were identified using GRIDS. Importantly, the five loci that were not detected in the 
GRIDS run of the discovery data but were reported as being associated with advanced 
AMD in the consortium paper (specifically, those SNPs near SLC16AB, TGFBR1, 
FRK/COL10A1, B3GATL, and RADS1) did not achieve genome-wide significant p-
values in the meta-analysis of the primary model results.  Instead, these loci were added 
to the list of 32 candidate loci genotyped in the replication set of 9,531 AMD cases and 
8,230 control samples because of results from other secondary analyses in the original 
study.  Because genome-wide significance was only achieved after meta-analyzing the 
discovery and replication data sets from the consortium paper, the absence of these loci 
from our list does not represent examples where meta-analysis outperforms GRIDS. 
Conversely, a comparison of both approaches on the same data revealed two instances 
where GRIDS offered superior detection power over standard meta-analysis. As shown in 
Table 6, the GRIDS algorithm identified two additional loci with modest effects 
(OR=1.13-1.14) that previously did not achieve genome-wide significance levels in the 
meta-analysis of the discovery data, but did exceed the GRIDS sensing cutoff of 
𝛼ீோூ஽ௌ = 1.63 × 10ି଻, after trimming about 70% of the search space. This represents a 
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40% increase in relative power to detect loci of weak effect size (OR<1.2) in this sample. 
Of the new loci detected in the discovery set, rs6795735 (p-value = 1.57 × 10ି଼) which 
is located near the gene AMADTS9, was among the SNPs with enough suggestive 
evidence in the other secondary analyses performed by the AMDGene Consortium to be 
included for replication.  After adding the additional 17,761 samples from the replication 
analysis, this variant was confirmed as being genome-wide significant.  Meanwhile, the 
locus detected in the PILRA/PILRB region of chromosome 7, rs705866 (p-value = 
8.34 × 10ି଼), was not reported in previously analyses and represents a novel GWAS 
finding in this dataset.  
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Table 6: Comparing GRIDS to meta-analysis of AMD discovery data 
SNP Ch Position Gene OR 
GRIDS           
p-value 
AMDGene         
p-value 
rs10490924 10 124214448 ARMS2/HTRA1 2.71 9.39E-322 4.0E-353 
rs12038333 1 196672454 CFH 2.35 1.2E-247 3.8E-288 
rs429608 6 31930462 SKIV2L 1.67 2.8E-44 2.0E-54 
rs2230199 19 6718387 C3 1.46 1.3E-20 1.7E-26 
rs17616836* 1 197216681 CRB1 1.41 2.2E-42 5.4E-48 
rs4420638 19 45422946 APOE 1.34 1.7E-13 3.2E-15 
rs13081855 3 99481539 COL8A1 1.28 8.4E-11 4.2E-11 
rs5754222 22 33103968 SYN3/TIMP3 1.23 7.0E-12 4.3E-12 
rs711752 16 56996211 CETP 1.2 2.3E-11 5.3E-12 
rs3130685 6 31206206 IER3/DDR1 1.19 1.0E-13 6.5E-15 
rs943080 6 43826627 VEGFA 1.18 4.4E-11 3.7E-12 
rs13278062 8 23082971 TNFRSF10A 1.17 1.7E-08 7.2E-10 
rs4698775 4 110590479 CFI 1.16 4.7E-08 1.6E-10 
rs920915 15 58688467 LIPC 1.14 3.3E-08 1.6E-09 
rs705866 7 99965285 PILRA/PILRB 1.14 8.3E-08 3.0E-06 
rs6795735** 3 64705365 ADAMTS9 1.13 1.6E-08 9.0E-08 
 
Table 6 show all of the loci passing the GRIDS significance threshold of 𝑝 <   1.63 ×
10ି଻. Bold SNPs indicate loci that previously did not attain genome-wide significance in 
the discovery meta-analysis.  Of these, rs705866 represents a novel finding for AMD risk. 
*While rs17616836 was found to be significant by both GRIDS and the original 
discovery meta-analysis, this SNP was not selected for replication by the AMDGene 
Consortium because of its proximity to the large effect CFH loci did not allow researcher 
to rule out cofounding influence on effect size to LD between the two SNPs.  
**The ADAMTS9 risk locus, rs6795735, was not found to be significant in the meta-
analysis of the primary AMD model, but was sent for replication in the original 
AMDGene Consortium experiment because of other supporting evidence. After meta-
analysis of the discovery and replication data set, this SNP was found to be genome-wide 
significant. The replication data set contained genotype data for 32 high priority SNPs 
from 17,761 independent samples that were not included in this analysis.   
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2.5.6. Discussion 
The GRIDS method identified association of AMD with three loci that were either 
not previously reported by the AMDGene Consortium and/or not identified as genome-
wide significant in their discovery meta-analysis which included the same datasets 
evaluated in this study.  The locus near CRB1, rs17616836, was identified by both 
approaches as being genome-wide significant (𝑝ீோூ஽ௌ < 2.2 × 10ିସଶ; 𝑝௠௘௧௔ < 5.4 ×
10ିସ଼).  However, this SNP was not selected for replication in the original AMDGene 
Consortium experiment because its proximity to the large effect risk variant in CFH, 
rs12038333, did not allow researchers to rule out a cofounding influence on effect size 
due to LD between the two SNPs.  However, the fact that GRIDS identified these loci as 
independent signals on separate haplotype blocks, is supportive evidence for the presence 
of two distinct signals in this region.  The argument for multiple independent signals 
within CFH has been made previously(M. Li et al.), and the potential for secondary 
signal near association peaks (particularly CFH) was investigated in the consortium 
paper.  After adjusting for the major effect SNP in CFH, investigators from the 
AMDGene Consortium found an additional independent signal in another SNP 7kb 
downstream of rs12038333. This is supportive of the signal found in this analysis near 
CRB1, 5.4kb upstream of rs12038333, which is also independent of CFH, though further 
testing in a larger cohort would be required to validate this hypothesis.  
As was shown in the final meta-analysis of the discovery and replication data sets 
in the consortium paper, the association detected near ADAMTS9 (rs6795735; 𝑝ீோூ஽ௌ <
1.6 × 10ି଼) is robust. Additionally, other subsequent genotyping experiments have 
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replicated this finding(Helisalmi et al.). This gene is a member of the ADAMTS (a 
disintegrin-like and metalloprotease domain with thrombospondin type I motifs) family, 
which contains 19 secreted mammalian metalloproteases that localize at the cell-surface 
and/or extracellular matrix. Knockdown experiments of ADAMTS9 have been linked to a 
development of spontaneous neovascularization in adult mice(Koo et al.). Microarray 
experiments using eye tissue samples from individuals with a high risk for AMD (as 
determined by CFH genotyping) demonstrated that expression of ADAMTS9 is 
significantly reduced (fold change = –2.6) compared to protein levels in healthy eye 
donors(Whitmore et al.). This combined body of evidence strongly implicates expression 
of ADAMTS9 as influential in AMD pathogenesis, although further experiments are 
needed to determine whether these differences are causative or downstream effects of the 
disease.  
Our most exciting result from the GRIDS analysis of AMD GWAS data was the 
novel finding of rs705866 in the PILRA/PILRB region of chromosome 7. Our peak SNP 
is nearest to PILRA, which was recently identified to be associated with AMD in our 
previous analysis of this dataset using a hypothesis-driven pathway approach (Logue et , 
Neurbiol Aging paper). PILRA encodes the paired-immunoglobulin-like type-2 receptor 
protein and is expressed on the surface of cells in the retinal pigment epithelium (RPE).  
This protein is known to bind with herpes simplex virus-1 (HSV-1), which is neurotoxic 
to sensory neurons in the eye and brain(Satoh and Arase; Shiratori et al.). Although there 
are no reports linking HSV-1 to AMD, the contribution of HSV to several ocular 
disorders including acute retinal necrosis (ARN) has been well documented(Newman and 
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Gooding; Lau et al.). Recently, PILRA has been shown to play a role in the entry of 
HSV-2 into the RPE, and this strain of the virus has also been linked to ARN(Shukla, 
Singh, and Shukla). 
2.5.7. Conclusions  
The overwhelming majority of novel findings emerging from major GWAS 
consoritum efforts are weak-effect risk variants(Manolio et al.).  This supports the 
hypothesis that modest effect risk variants make up a large portion of the missing 
heritability still left unexplained by the current collection of genetic markers for common 
diseases.  While increasingly larger study disigns that enroll thousands, if not tens of 
thousands, of more patients will shed light on these markers, there is an immediate need 
for better algorithms that can efficiently detect associations with weak-effect risk loci 
using existing data.  Our simulation experiments demonstrated a robust range of 
experimentally feasible conditions where GRIDS, has superior detection power over 
meta-analysis for weak-effect variants. Moreover, application of this approach to a very 
large AMD GWAS dataset showed that GRIDS is not prone to false negative results for 
risk loci in the modest to large effect range. In contrast, the novel GWAS association on 
chromosome 7 near PILRA/PILRB (OR=1.14) demonstrates the utility of GRIDS for 
analysis of  multiple GWAS data sets.  The putatuve risk variant near ADAMTS9 has 
already been replicated(Fritsche et al.; Helisalmi et al.) and functional studies strongly 
implicate expression of this gene as being linked to AMD eitology(Whitmore et al.; Koo 
et al.).   
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The successful application  of GRIDS to an existing GWAS dataset confirms the 
observations in the simulation study that the robustness of the GRIDS algorithm is 
dependent on the initial decisions to parse the data into the focusing and sensing steps.   
Despite not having access to the raw genotype data for the predicted ideal focusing data 
set (as estimated by Equation 2.1), GRIDS still identified novel weak-effect loci from the 
discovery GWAS data set without missing any of the previously established risk loci 
(sensitivity =100%).  While it is uncertain whether the association with rs705866 will 
survive replication efforts, 14 of the 16 predicted top loci from the GRIDS 
implementation  have  already  been  confirmed  in  the  AMDGene  Consortium’s  replication  
analysis (specificity > 87.5%). In summary, application of GRIDS to simulated data sets 
and AMD GWAS data, demonstrates that DS can have superior power over traditional 
meta-analysis techniques to detect weak-effect loci in a wide range of predictable 
experimental conditions. This tool offers immediate utility to researchers seeking to 
derive novel insights from existing data sets, and promises to forward the discovery of 
new risk variants in multiple heritable diseases.    
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3. Integrating WES data with SNP data to detect rare causal variants  
 
3.1. Genetics  of  Alzheimer’s  Disease 
3.1.1. Introduction 
Alzheimer’s  disease (AD) is the most common form of dementia and currently 
affects nearly 34 million people worldwide with a prevalence of about 5.4 million cases 
in the United States alone. Given the rapid growth rate of aging populations in developed 
countries, the global projection of AD cases is expected to triple in 40 years(Association; 
Barnes and Yaffe). The primary risk factor for AD is age, and it is estimated that 1 in 8 
Americans over the age of 65 have the disease(Alzheimer’s Association). Other 
environmental risk factors include diet, physical inactivity, cognitive inactivity, obesity, 
hypertension, diabetes and smoking(Barnes and Yaffe). Meanwhile, a large number of 
genetic markers for AD risk have recently been reported by multiple large GWAS 
consortia and may contribute to more complete models for inherited risk. However, one 
limitation of these findings is that they originate from studies primarily conducted in 
individuals of Caucasian descent, leaving an unmet need to replicate these results or 
identify new genetic risk markers in other populations.  Moreover, with most of the new 
genetic risk loci for AD having modest the effect size estimates (OR between 1.1 and 1.3), 
these massive GWAS endeavors fall short of delivering a complete picture of the genetic 
underpinnings of AD. While GWA studies tend to focus on more common SNPs (MAF > 
5%), it has been hypothesized that rare highly penetrant variants in previously known and 
unknown genes may account for much of the liability for the disease. Given that rare 
protein coding variants explain a significant proportion of the Mendelian early-onset 
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form AD (EOAD), the possibility of finding rare variants that explain contribute to late 
onset AD seems promising.     
In this thesis chapter we outline a filtering strategy to identify risk variants in a 
small-scale sequencing experiment and establishing their relevance to AD by association 
testing in a larger group of AD cases and controls. Furthermore, we demonstrate that this 
protocol allows for efficient detection of rare, but highly penetrant, risk-loci for AD. 
Importantly, our work focuses on identifying AD risk loci from case-control data sets 
comprised of individuals of African American descent, a largely understudied population 
for AD.  In the initial phase of the experiment (Discovery Phase I) we performed whole-
exome sequencing of 7 African American AD cases from the Multi-Institutional 
Research on Alzheimer Genetic Epidemiology (MIRAGE) Study. More than 80,000 
variants were identified and subjected to a series of QC and filtering steps, and 64 of 
these variants were prioritized for genotyping in a larger cohort of 809 AA subjects. 
Statistical analysis revealed nominally significant association with two variants in the A 
kinase anchor protein 9 gene (AKAP9: p=0.014 and p=0.037). Subsequent replication 
analysis of these variants in an even larger sample of AAs  (N= 2,906) confirmed their 
association with AD (p= 0.00022). Additional bioinformatic analysis strongly supports 
the hypothesis that thesis protein-coding risk variants are functionally relevant to the 
etiology of AD, and rules out confounding effects due to other variants in LD with these 
loci.      
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3.1.2. Genetics  of  Alzheimer’s  Disease 
There are two generally recognized forms of AD.  The rarer form of the disease 
(representing less than 1% of all AD cases) is known early-onset AD (EOAD) and is 
usually diagnosed in patients ages 60 and younger, as early as age 30(Holtzman, Morris, 
and Goate). EOAD is associated with an autosomal dominant inheritance 
pattern(Goldman et al.). Multiple genetic studies have identified rare mutations that fully 
explain the transmission of EOAD in select lineages, with the majority of these mutations 
appearing in the APP and PSEN1 genes. Mutations in the PSEN2 gene have also been 
established as deterministic markers for EAOD, however, causal variants in this gene are 
significantly rarer with most recorded mutations in this gene arising within a single 
pedigree know as the Volga-German(Bekris et al.). 
The more commonly occurring late-onset  Alzheimer’s  disease (LOAD) is 
typically diagnosed in patients older than 65 years of age. The average person has an 
estimated 10-12% risk of developing LOAD in his or her lifetime(Schu et al.). Given that 
the  vast  majority  of  Alzheimer’s  patients  are  diagnosed  with  LOAD,  by  convention  the  
latter  form  of  the  disease  is  often  abbreviated  as  simply  “AD”  and  we  will adopt this 
same terminology from here out in the manuscript.  Unlike EOAD, late-onset AD is not a 
Mendelian disease and is sometimes referred to as sporadic AD because of its complex 
inheritance patter. Nonetheless, AD still has a strong genetic component (heritability = 
75%), as evidenced by an increased lifetime risk in first-degree relatives of patients with 
AD ranging from 20-25%(Bekris et al.; Bienvenu, Davydow, and Kendler).  
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To date, the most robust genetic risk marker for AD is the apolipoprotein E 
(APOE) gene (Kinoshita and Clark) which was identified by linkage analysis and 
subsequent association testing of genes under the linkage peak. There are three common 
APOE alleles,  labeled  as  ε2,  ε3,  and  ε4,  which are found in the populations of western 
and northern European ancestry at frequencies of 8%, 77% and 15% respectively(Leoni). 
The APOE-ε4  allele  carries  the  greatest  risk  for  AD,  (OR=3.69  relative  to  most  common  
ε3/ε3 genotype),  while  the  ε2  allele  has  been  suggested  to  have  a  protective  effect(Corder 
et al.; Saunders et al.). In contrast, the majority of AD associations with other loci, which 
have more subtle effect sizes (OR between 1.1 and 1.3), were derived from large GWAS 
consortium efforts.  
3.1.3. Genetic risk markers for AD in African Americans 
African Americans (AAs) are about twice as likely as non-Hispanic whites 
(NHWs) to have AD(Alzheimer’s Association). Although differences in AD etiology 
across populations have been widely studied, they are still poorly understood. The 
occurrence of multiple demented individuals in African American families is 
significantly higher than in white families, although the genetic risk of AD is similar 
between these 2 populations(Green et al.). The increased familial risk in African 
Americans may be the result of higher rates of other risk factors, such as poor education, 
diabetes mellitus, and smoking. However, comparisons of risk in AA and NHW cohorts 
are complicated by differences in assessment of cognitive decline across studies and by 
population differences in willingness and/or ability to participate in medical 
research(Connell et al.; Dilworth-Anderson et al.; M. Logue et al.).   
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Even though the proportion of risk due to genetic influences is similar in AAs and 
NHWs, there is evidence that the genetic architecture of AD differs between these two 
populations.  For example, the effect of APOE 4 on AD risk is considerably weaker in 
AAs than NHWs(M. Logue et al.), although this difference may be accounted for in part 
by the age-dependent effect of 4(Graff-Radford et al.). While it is conceivable that the 
AA studies are underpowered compared to studies with NHWs, the differences in effect 
sizes between common risk loci also may be due to differences in the linkage 
disequilibrium (LD) structure between AAs and NHWs or population-specific causal 
variants underlying the associations. For example, two recent AD-GWA studies 
replicated an association with ABCA7 in AAs, and in both experiments the risk associated 
with this locus approached that of APOE 4 in AAs(M. Logue et al.; Reitz et al.). Still, a 
large proportion of the genetic liability of AD in AAs remains unexplained, and it is 
hypothesized that much of the heritability may be ascribed to uncommon (frequency < 
5%) or rare (frequency < 1%) variants which would be undetectable in GWAS except in 
very large samples(Cirulli and Goldstein).   
3.2 Methods 
3.2.1. Sequenced Samples: Discovery Phase I  
While GWAS approaches focus on common SNPs, Next Generation Sequencing 
(NGS) methodologies offer the potential to identify rare or private risk variants that 
would elude most SNP-chip designs. Given that classical models of genetics suggest that 
highly deleterious risk loci would be selected against in the population, it is reasonable to 
expect that rare or private risk variants may exert relatively higher effects on disease risk 
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compared to most common disease-associated variants(Gibson,  “Rare  and  Common  
Variants:  Twenty  Arguments.”;;  Cirulli  and  Goldstein). However, identifying novel rare 
variants is inherently challenging when sampling only a portion of the target population. 
To improve the odds of detection, we employed an efficient study design to identify 
highly penetrant disease variants by sequencing individuals from families with multiple 
affected members who are thus more likely to harbor rare causal risk variants. Potentially 
disease-causing variants identified in familial cases were then genotyped in other family 
members and in a larger sample of unrelated individuals to evaluate association with 
disease. To this end, we performed whole-exome sequencing of seven African American 
AD cases from the Multi-Institutional Research on Alzheimer Genetic Epidemiology 
(MIRAGE) Study.  Patient samples were prioritized for selection based on the number of 
affected members in their family.  Thus, larger families with evidence of AD occurring in 
multiple generations of the lineage were more likely to be sampled in the whole-exome 
sequencing stage of this experiment over pedigrees that were not as well represented in 
the MIRAGE database and/or those families that exhibited a lower frequency of AD 
transmission.     
3.2.2. Genotyped Samples: Discovery Phase II and Replication 
In our study, protein-coding variants identified as potentially AD-related from the 
Discovery Phase I analysis were genotyped in an additional set of 816 AA samples. 
These samples were taken from two studies; the MIRAGE cohort and the GenerAAtions 
cohort (see Table 7) both described elsewhere(M. Logue et al.). Subjects included in this 
analysis were cognitively assessed at 60 years of age or older. To replicate the findings in 
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the discovery cohort, the most significant variants were subsequently genotyped in a 
subset from the Alzheimer Disease Genetics Consortium (ADGC) AA sample, referred 
henceforth as the replication sample (see Table 8). The ADGC AA cohort is described in 
detail elsewhere, though it is worth noting that replication cohort for this study excludes 
the MIRAGE and GenerAAtions data sets which were included in the ADGC GWAS in 
AAs(Reitz et al.). All studies were performed with appropriate institutional review board 
approval and informed consent was obtained from all study participants.  
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Table 7: Samples in Discovery Phases I & II 
 
Group 
 
N 
 
AD Cases 
 
Controls 
 
Males 
 
Females 
Mean Age 
(SD) 
APOE 4 
frequency 
WES  
Subjects 7 7 (100%) 0 (0%) 3 (43%) 4 (57%) 79.4 (5.2) 21% 
Analyzed 
MIRAGE 
subjects 
408 199 (49%) 209 (51%) 121 (30%) 287 (70%) 75.1 (8.1) 34% 
Analyzed 
GenerAAtions 
Subjects 
408 223 (55%) 185 (45%) 173 (42%) 235 (58%) 79.5 (6.7) 29% 
Total Discovery 816 422 (52%) 394 (48%) 294 (36%) 522 (64%) 77.3 (7.5) 32% 
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Table 8: Characteristics of the genotyped samples in AA replication cohort 
 
Group 
 
N 
 
AD Cases 
 
Controls 
 
Males 
 
Females 
Mean Age 
(SD) * 
APOE 
4 freq 
ADC 24 4 (17%) 20 (83%) 8 (33%) 16 (67%) 73.6 (5.8) 14% 
CHAP 328 177 (54%) 151 (46%) 105 (32%) 223 (68%) 81.7 (6.6) 18% 
U. Miami 246 82 (33%) 164 (67%) 63 (26%) 183 (74%) 72.7 (8.4) 26% 
Washington U. 165 125 (76%) 40 (24%) 39 (24%) 126 (76%) 75.5 (7.6) 29% 
U. Pittsburgh 201 109 (54%) 92 (46%) 55 (27%) 146 (73%) 76.7 (7.4) 30% 
AAG - Columbia 242 20 (8%) 222 (92%) 44 (18%) 198 (82%) 69.8 (7.6) 21% 
AAG – Miami 199 40 (20%) 159 (80%) 46 (23%) 153 (77%) 71.7 (7.8) 25% 
AAG - NC A&T 226 61 (27%) 165 (73%) 68 (30%) 157 (69%) 71.3 (8.6) 27% 
AAG – Vandy 124 37 (30%) 87 (70%) 25 (20%) 99 (80%) 72.1 (8.8) 29% 
Mayo Clinic 308 80 (26%) 228 (74%) 68 (22%) 240 (78%) 78.2 (7.2) 24% 
MSSM 43 29 (67%) 14 (33%) 17 (40%) 26 (60%) 82.7 (10.0) 28% 
NIA-LOAD 15 6 (40%) 9 (60%) 1 (7%) 14 (93%) 72.5 (7.0) 25% 
ROS/MAP 130 28 (22%) 102 (78%) 54 (42%) 76 (58%) 81.0 (5.3) 18% 
Vanderbilt U. 34 9 (26%) 25 (74%) 7 (21%) 27 (79%) 70.4 (6.4) 24% 
WHICAP 621 230 (37%) 391 (63%) 159 (26%) 462 (74%) 80.8 (6.4) 19% 
Total 2,906 1,037 (36%) 1,869 (64%) 759 (26%) 2,146 (74%) 75.3 (8.5) 23% 
67 
  
68 
3.2.3. Whole Exome Sequencing (WES) quality control 
Whole-exome capture was performed using the Agilent SureSelect Human All 
Exon kit. Sequencing was performed using the Illumina GA IIx platform. The alignment 
of the 80 bp single-end reads was completed with the Burrows-Wheeler Aligner (BWA) 
algorithm(Li  and  Durbin,  “Fast  and  Accurate  Short  Read  Alignment  with  Burrows-
Wheeler Transform.”;;  Li  and  Durbin,  “Fast  and  Accurate  Long-Read Alignment with 
Burrows-Wheeler  Transform.”). SNP discovery and quality filtering was completed using 
a pipeline based on the Genome Analysis Toolkit (GATK)(McKenna et al.; DePristo et 
al.). The success rate for aligning the 80 bp sequences from the seven subjects was 96.3% 
with 17.5x mean coverage within target regions. Prior to filtering, 88,867 SNPs were 
identified and the transition:transversion ratio for these SNPs (Ti/Tv) was 2.8, consistent 
with what one would expect for human exonic-data(Pattnaik et al.). After filtering for 
read and variant quality (read depth > 10, depth quality score > 5, map quality score > 30) 
total of 81,335 SNPs remained. The Ti/Tv ratio for these surviving SNPs was 2.9, which 
is still within normal limits of 2.8-3.0 for coding regions of the genome(Pattnaik et al.).  
While these filtering parameters for read depth and quality score are somewhat liberal, 
only SNVs observed in more than one sequenced AD-case were included in subsequent 
analysis to protect against sequencing errors. After applying this restriction that variants 
had to be recurrent in the seven samples,  the  final  number  of  eligible  SNV’s  was  reduced  
to 50,904.  
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3.2.4. Variant Prioritization 
In an effort to prioritize novel variants that passed the QC measures, data were 
filtered to exclude SNPs already present in the version of dbSNP that was current at the 
time of the analysis (dbSNP build 132). After removing previously known SNPs, a total 
of 1,364 SNPs remained. Of these, 431 SNVs were non-synonymous protein-coding 
variants and given higher priority for further consideration based on an assumed greater 
potential for functional impact over synonymous coding variants. Annotation of these 
surviving SNVs revealed that 12 of them were in genes listed in AlzGene(Kinoshita and 
Clark). Notably, only one of these SNPs (rs149704584) was in a gene (CD33) with 
replicated association to AD 
To better understand the functional relevance of the remaining 419 SNVs, a 
network and pathway analysis including the genes harboring these variants and the 15 
well-established AD risk genes(Schu et al.) was performed using INGENUITY Pathway 
Analysis (IPA) software (http://www.ingenuity.com/products/ipa).  IPA’s  network  
generation algorithm aims to create local gene-gene interaction networks which reflect 
the interconnectivity of a list of focus genes that are input to the software by the user. In 
brief, the algorithm begins by finding the most significantly interconnect gene in the list 
of focus genes.  Here interconnectivity is measured by the number of triangle networks, 
or pairs of connected genes, that a given focus gene is connected to in IPA Global 
Molecular Network. Other focus genes are added to the network in order of the overlap 
specificity the existing network and the network for first-degree neighbors of each focus 
gene. By prioritizing focus genes based on the specificity of the overlap, rather than the 
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magnitude, the algorithm biases against network hub genes which are likely to have high 
overlap with any given gene set, but low specificity. After local networks are generated, a 
network  score  is  assigned  to  each  using  a  Fisher’s  exact  test  to  determine  the  likelihood  
of observing the same number of seed genes in a random set of genes of number as the 
local network taken from the Global Molecular Network. While this score will rank local 
networks by relative density of seed genes, one cannot infer any statistical significance 
from this score. However, the motivation theory behind this ranking score is that more 
highly-interconnected genes in the network are likely to represented latent biological 
function and molecular relationships. Assuming this hypothesis is correct and based on 
results from our own IPA analyses, we prioritized 46 genes that occurred in local 
networks with the established AD genes (see Figure 8).  Because nodes in the networks 
represent either established or inferred protein-protein interaction, we hypothesized that 
genes nearer to the established AD risk genes in the local networks were more likely to 
influence expression of the known AD genes and therefore should be further prioritized 
for subsequent genotyping.   
In the combined set of variants occurring in AD genes as annotated by AlzGene 
and the list of genes occurring in the local IPA networks described above, there were a 
total of 63 non-synonymous coding variants that were deemed to be high priority SNVs 
based on the criteria previously described. Forty-four of the 63 SNPs were successfully 
genotyped in the cohort of 441 cases and 426 controls. 
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Figure 8: Networks derived by IPA containing established AD genes 
 
Networks derived by IPA software containing previously-known AD genes (green) and 
genes containing non-synonymous SNPs identified through whole-exome sequencing 
(red). These networks are characterized by genes with biological functions related to: (A) 
cellular assembly and organization, nervous system development and function, and 
carbohydrate metabolism; (B) cell-to-cell signaling and interaction, cellular assembly and 
organization, and nervous system development and function; (C) hematological system 
development and function, renal and urological system development and function, and 
cellular compromise. 
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3.2.5 Statistical Analysis 
The Discovery Phase II tests for association with AD were performed using R. 
Modeling rare variants poses a challenge to logistic regression techniques rare alleles can 
cause numerical instability in curve fitting algorithms thus preventing these 
computational methods from converging on a single result. As a result, the significance 
of allele frequency differences between cases and controls was determined using a one-
sided  Fisher’s  exact  test in the discovery phase of this analysis, rather than by a 
regression technique.  A one-sided test for significance was performed since our search 
was designed to identify deleterious (and not protective) rare variants. 
AD-associated population substructure within the discovery sample that might 
confound the results was evaluated in two steps. First, principal components of 
substructure were calculated from GWAS data for the discovery cohort using 
EIGENSTRAT(Price et al.) based on 10,000 imputed SNPs with minor allele frequencies 
>5%. Logistic regression was performed using GEE to model risk of AD associated with 
any of the first 10 principle components. GEE is well suited for a mix of family and case-
control data because it allows for inclusion of singletons and related individuals (Zeger 
and Liang). Ultimately, no evidence of AD-associated population substructure within the 
discovery sample was found (all p>0.05 for tests of association between AD and each of 
the first 10 principal components)(M. Logue et al.).    
Association testing in the replication phase of the experiment was also conducted 
using logistic regression adjusting for sex and study site. The size of the cohort was 
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significantly larger and, thus, regression models are more likely to converge to a final 
result.   
3.3. Results 
3.3.1. Discovery Phase 
Initial sequencing results revealed a total of 88,867 variants identified by WES in 
the Discovery Phase I cohort of 7 AA case samples. After applying quality control filters 
(described in detail in Section 3.2.3), 63 SNVs from 58 genes were selected for further 
study and 44 of these SNVs were successfully genotyped in the entire sample. Detailed 
results of these genotyped SNVs are presented in Table 9, including allele counts 
between cases and control samples and corresponding results from the 1-sided  Fisher’s  
exact tests. The majority of genotyped SNVs were rare (29 SNVs had a MAF<1%). 
Nominally significant results were obtained from the AKAP9 SNPs rs144662445 (p = 
0.014, OR = 8.4) and rs149979685 (p = 0.037; the OR for rs149979685 could not be 
estimated because the rare allele was not observed in any controls) (see Table 10).  To 
simplify descriptions of the subsequent analyses, henceforth we refer to the group of all 
patients having at least one of the 2 rare AKAP9 variants as being AKAP9-positive (or 
AKAP9+). Interestingly, no AKAP9+ subjects were observed having the minor allele of 
rs149979685 but not rs144662445. Furthermore, no homozygotes were observed for 
either SNP. Only one control subject had rare alleles for both rs144662445 and 
rs149979685, however this individual was excluded from all analyses due to age, being 
the 54 year-old unaffected sibling of an AD proband. The remainder of the AKAP9+ 
subjects are all unrelated according to their self-reported data and identity by descent 
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(IBD) estimates as calculated by PLINK (Purcell et al.) using genome-wide SNP data. 
Furthermore, a principle components (PC) analysis in EIGENSTRAT indicated that these 
subjects were not members of a clearly defined population subgroup within AAs (see 
Figure 9).  
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Table 9: Genotyped SNPs from Discovery Phase II 
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NoC2L 1 888563 rs150127608 1 5 819 3 773 0.40 
ISG15 1 949491 rs148041041 1 0 832 0 784 1.00 
AGRN 1 987191 rs139415524 1 2 824 4 776 0.90 
FCRLA 1 161681238 rs144830049 1 5 819 3 777 0.39 
ATP2B4 1 203672867 rs145963279 1 19 811 10 768 0.09 
PLX02 1 208215558 rs144005934 1 1 831 0 782 0.52 
AGT 1 230838903 rs143479528 1 3 827 3 781 0.68 
IFIH1 2 163137881 rs147000317 1 7 819 4 778 0.31 
LRP2 2 170134388 rs145094511 1 0 830 0 784 1.00 
ITGA9 3 37774225 rs142726080 1 26 804 18 760 0.20 
SCN5A 3 38646398 NA 1 0 828 2 782 1.00 
NKTR 3 42678946 rs146815110 0.26 9 823 21 761 1.00 
LRAT 4 155665876 rs147855559 1 0 832 0 782 1.00 
HAND2 4 174448432 rs140861359 1 2 828 1 783 0.52 
GPLD1 6 24436908 rs140754732 1 1 831 1 777 0.77 
TAP2 6 32798457 rs150253319 1 19 811 14 770 0.30 
TAP2 6 32802938 rs140654840 0.33 15 817 18 764 0.81 
TNFAIP3 6 138195991 rs146534657 1 0 832 0 782 1.00 
GRM1 6 146755454 rs144944927 1 14 816 21 761 0.94 
GLI3 7 42007460 rs146130351 1 14 818 18 760 0.86 
AKAP9 7 91709085 rs144662445 1 9 835 1 785 0.01 
AKAP9 7 91732110 rs149979685 1 5 837 0 788 0.04 
TRIP6 7 100466396 NA 1 18 810 15 767 0.43 
MUSK 9 113530236 NA 1 2 830 0 784 0.27 
RALGDS 9 135985773 rs140586035 1 15 807 13 763 0.49 
TACR2 10 71167027 rs142415572 0.43 61 771 51 731 0.29 
SORCS3 10 106974224 NA 1 3 825 2 780 0.53 
KNDC1 10 135015178 rs141463252 1 6 824 3 777 0.29 
LRP4 11 46911956 rs138878258 1 6 826 2 778 0.17 
STX3 11 59562950 rs142968661 0.67 18 818 17 711 0.66 
BAD 11 64051762 NA 1 0 832 0 784 1.00 
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Table 9 (continued) 
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SPTBN2 11 66475201 NA 1 0 832 0 780 1.00 
CEP290 12 88512485 rs147371999 1 13 819 16 768 0.82 
ACACB 12 109683516 rs145398869 1 0 832 1 783 1.00 
KL 13 33591385 NA 1 4 824 5 779 0.77 
KIF26A 14 104642981 NA 0.85 3 745 7 653 0.97 
PELP1 17 4579700 rs147186006 1 12 820 19 763 0.95 
MYH13 17 10247309 rs144732640 1 7 825 10 774 0.86 
NoS2 17 26110055 rs149623743 1 3 829 2 782 0.53 
IGFBP4 17 38612790 NA 1 0 838 0 722 1.00 
STXBP2 19 7712054 rs150174842 1 6 824 6 776 0.65 
XRCC1 19 44047554 NA 1 0 832 0 782 1.00 
CD33 19 51742799 rs149704584 1 1 827 0 782 0.51 
CNGA2 X 150912171 rs150539917 0.21 74 756 67 709 0.46 
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Figure 9: Principle Component Plot of Discovery Data Set 
  
Plots of the first 10 principal components of population substructure in the AA sample of 
436 AD cases and 424 controls derived by EIGENSTRAT based on 10,000  MAF>5% 
markers from a whole-genome genotyping panel. The color of the plotting symbols 
indicates AKAP9 genotype: Black= subject lacks rs144662445 and rs149989685 variants, 
Red= subject has rs144662445 variant, Green= subject has both rs144662445 and 
rs149989685 variants. 
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Table 10 : Top Results from Discovery Phase II Analysis 
Gene Position SNP ID Freq  Cases 
Freq 
Controls P 
AKAP9* 7:91709085 rs144662445 0.011 0.0013 0.014* 
AKAP9* 7:91732110 rs149979685 0.0060 0.000 0.037* 
ATP2B4 1:203672867 rs145963279 0.023 0.013 0.092 
LRP4 11:46911956 rs138878258 0.0072 0.0026 0.17 
ITGA9 3: 37774225 rs142726080 0.032 0.024 0.20 
 
The most significant associations between AD and genotyped SNPs in the discovery 
cohort. 
 
Abbreviations:  AD, Alzheimer disease; Freq, frequency; SNP, single-nucleotide 
polymorphism. 
* Genotypes for AKAP9 SNPs confirmed via Sanger sequencing. 
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Table 11: Characteristics of AKAP9+ Discovery Samples 
Study 
WES 
sample Sex APOE Age* 
AD 
Status rs144662445 rs149979685 
GenerAAtions No F 34 75 Control AG CC 
MIRAGE No F 44 55** Control AG CT 
MIRAGE No F 33 86 Case AG CC 
MIRAGE No M 23 74 Case AG CC 
MIRAGE No F 34 82 Case AG CC 
GenerAAtions No F 33 88 Case AG CC 
MIRAGE No F 33 81 Case AG CT 
MIRAGE Yes F 34 82 Case AG CT 
MIRAGE Yes F 44 84 Case AG CT 
MIRAGE No M 33 78 Case AG CT 
GenerAAtions No M 33 64 Case AG CT 
GenerAAtions No F 33 71 Case AG CT 
GenerAAtions No F 23 91 Case AG CT 
 
Table 11 summarizes the characteristics of the 13 AA Subjects in the discovery samples 
with at least one AKAP9 variant in rs144662445 and rs149989685. 
*Age at assessment. 
**Excluded from analysis due to age <60 at time of assessment 
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3.3.3. Replication Results 
 
We sought replication of the association with the two AKAP9 SNPs in a subset of 
the African American sample from the ADGC. Valid genotypes for both SNPs were 
obtained in 1,037 AD cases and 1,869 controls. Using a GEE logistic regression model 
adjusted for sex and sample site, significant associations were observed for the minor 
alleles of both rs144662445 (p=0.0022, OR=2.75) and rs149979685 (p=0.0022, 
OR=3.61) (see Table 12). This demonstrates that the initial association observed in the 
discovery data is replicable in a larger independent sample. 
3.4. Bioinformatic Analysis 
3.4.1. Haplotype Analysis 
To examine the possibility that an untested AD causal variant in AKAP9 or 
surrounding region could account for the observed association, we compared haplotypes 
of AKAP9+ and AKAP9- individuals  in  the  discovery  sample.  The  5’  end  of  AKAP9 
overlaps with a large LD block that includes the neighboring genes CYP51A1, KRIT1, 
ANKIB1, and LRRD1 (see Figure 10). Haplotype analysis of the 10 common (MAF>0.05) 
AKAP9 SNPs in the GWAS-genotyping array revealed that all of the AKAP9+ subjects 
harbored the same haplotype, referred to as HAP0 (see Table 13). Haplotype analysis 
using PLINK revealed that the frequency of HAP0 is greater in AD cases (6.1%) 
compared to unrelated controls (4.1%), although this difference is not quite significant 
(p=0.071; chi-squared test). A review of the initial WES data showed that no other coding 
variants in HAP0 were observed in the two AKAP9+ subjects found in the Discovery 
Phase I cohort.  
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To corroborate the observation that the two rare AKAP9 variants only occurred 
on HAP0, genomic data from 246 individuals of African-descent subjects, including 88 
Yorubans from Nigeria, 97 Luhyans from Kenya, and 61 AAs from the American 
Southwest, were obtained from the 1000 Genomes database.  Analysis of the phased 
genotypes for the 10 SNPs defining HAP0 revealed 11 individuals have one copy of 
HAP0 at this region of chromosome 7. Three of these 11 individuals (NA18499, 
NA19448, and NA20126) had minor alleles at both rs144662445 and rs149979685, and 
one individual (NA20298) only had the rs144662445 variant. Neither variant was found 
in any other individual in the previously described subset of the 1000 Genomes samples 
of African descent, supporting the hypothesis that these variants occur only on HAP0. 
Importantly, these AKAP9 variants were observed in each of the three African-descent 
groups represented in 1000 Genomes, suggesting that these AKAP9 variants are relatively 
ancient. 
3.4.2. Phylogenetic analysis 
Next, we performed phylogenetic analysis using all of the SNP information in the 
genomic region spanned by HAP0 (chr7:91700000-91732110, as defined by the hg19 
build of the human genome assembly).  This region contains 385 SNPs reported in the 
1000 Genomes database that were used in the analysis described below. After redefining 
the set of HAP0 alleles based on whether these phased blocks are also positive for at least 
one, only one, or neither of the rare AKAP9 variants (i.e. HAP0+, HAP0+1, and HAP0- 
respectively), we then performed a hierarchical clustering analysis of all the phased 
alleles present in the 11 individuals of African-descent in 1000 Genomes database who 
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were positive for any of the HAP0 derivatives (see Figure 11A). Clustering analysis was 
based on the similarity between phased haplotypes calculated by the dist() function as 
implemented in R using the Euclidean distance defined by the genotypes of the 385 SNPs 
in the region of interest.  After measuring the pairwise similarity between all 22 
haplotypes, hierarchical clustering was performed using the hclust() function, also 
available under the stats package in R.  
Analysis of the expanded list of 385 SNPs spanning the LD block defined by 
HAP0 confirmed clear separation between the 11 HAP0 and 11 non-HAP0 alleles as well 
as a distinct clustering of the HAP0+ alleles relative to the HAP0- alleles.  Furthermore, 
there is a branch point separating the HAP0+ haplotype containing one AKAP9 variant 
(designated HAP0+1) from the haplotype containing both AKAP9 variants (HAP0+2), 
suggesting that the presence of minor allele at rs144662445 predates the appearance of 
variant at rs149979685 in the population.   
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Table 12: AKAP9 Replication Results 
SNP ID Frequency 
Cases 
Frequency 
Controls 
Odds 
Ratio 
95% CI P 
rs144662445 0.011 0.0043 2.75 1.38 -5.61 0.0022 
rs149979685 0.0072 0.0027 3.61 1.51-9.00 0.0022 
 
The association between AKAP9 variants and AD using a logistic regression adjusted for 
sex and study site in the replication cohort. Abbreviations: AD, Alzheimer disease; CI, 
confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism. 
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Figure 10: LD Block Containing AKAP9 Gene 
 
Figure 10 Shows the linkage disequilibrium (R2) plot of AKAP9 and surrounding region 
based on HapMap YRI reference panel of SNPs.    
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Table 13: Haplotype Frequencies of AKAP9 LD Block 
Haplotype * Frequency 
AGAGGAGAAC 0.425 
GAAAAGAGGA 0.218 
GGCAGGAGGA 0.129 
GGAAGGAGGA 0.118 
GGAAGGAAGC  † 0.052 
GGAGGAGAAC 0.045 
 
Estimated frequencies of >1% MAF AKAP9 haplotypes based on SNPs from GWAS 
genotyping. 
* Alleles for SNPs rs1859037, rs2299233, rs2282973, rs6465347, rs2158138, rs733957, 
rs2079082, rs13239875, rs4265, and rs1063243, respectively. 
†  Haplotype  HAP0  containing  rare  variants  at  rs144662445  and  rs149989685.     
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Figure 11: Dendrogram of Haplotypes in AKAP9 LD Block 
 
Examination of the 1000 Genomes subjects with the haplotype containing the two 
identified AKAP9 variants including (A) a phylogenetic dendrogram of haplotypes and 
(B) positions of infrequent SNPs (<5% MAF) shared by haplotypes with 0, 1, and 2 
variants. Key: HAP0: The background haplotype which contains the two identified 
AKAP9 variants. HAP0+ the background variant with one or more of the two putatively 
AD-associated variants; HAP0- the background haplotype without either AD-associated 
variants; HAP0+1 the background haplotype with one of the AD-associated AKAP9 
variants; HAP0+2 the background haplotype with both AD-associated AKAP9 variants.  
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3.4.3. Characterization of Haplotype in Public Domain 
The LD block defined by HAP0 spans multiple genes including AKAP9 which 
harbors the variants identified in this analysis as being associated with risk for AD 
(Figure 10). Therefore, to ascertain other plausible exonic SNPs that might explain the 
observed association with AKAP9, we identified all SNPs in the 1000 Genomes AA 
subset that also occur on HAP0+ but are not present on HAP0-.  For this analysis we 
focused only on the SNPs in the LD block on chromosome 7 spanning 91.3 Mb to 92.1 
Mb. We observed that the three subjects with HAP0+2 haplotypes shared 69 variants 
with MAF< 10% that were not observed in subjects with the HAP0- haplotype. Of these 
variants, rs144662445 and rs149979685 in AKAP9 are the only coding SNPs. 
Comparison of the single HAP0+1 haplotype in 1000 Genomes to all of the HAP0- 
phased alleles revealed 49 variants with MAF< 10%, which were not observed on the 
low-risk haplotype.  There were 2 additional non-synonymous coding variants in AKAP9 
on this HAP0+1 hapolotype, rs186619641 and rs201858518.  Interestingly, these SNPs 
appear unique to individual NA20298 in the 1000 Genomes database. Using only 1000 
Genomes data it could not be concluded whether these two other non-synonymous 
variants are shared by all subjects in our study with HAP0+1 or represent private 
mutations in the 1000 Genomes individual who harbored one copy of HAP0+1 
(NA20298). However, an investigation of the non-overlapping data in the Exome 
Sequencing Project (ESP) database suggests the later scenario (that rs186619641 and 
rs201858518 are private variants) is true. Among 2,303 AA subjects in the ESP database, 
there are three individuals with HAP0+1 but no individuals with rare alleles at 
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rs186619641 or rs201858518. This demonstrates that the two AD-associated variants 
defining HAP0+1 and HAP0+2 are not surrogate markers for rs186619641 and 
rs201858518. Therefore, based on our examination of HAP0+ in public databases, we 
conclude that rs144662445 and rs149979685 are the only plausible AD-related coding 
variants on the HAP0 background haplotype within AKAP9 and the surrounding region. 
3.5.  Discussion 
3.5.1. Relevance of AKAP9 to AD 
AKAP9, located on chromosome 7q21-22, encodes a large (>450 kD) member of 
the A kinase anchoring protein (AKAP) family. AKAPs are a diverse family of proteins 
but share a common binding site for protein kinase A (PKA) and function as scaffolding 
proteins for this and other signaling molecules throughout the cell. Importantly, PKA  
(also known as cyclic AMP dependent protein kinase) has been linked to the regulation of 
synaptic plasticity in the brain(Sanderson  and  Dell’Acqua).  
Alternative splicing of the gene results in 2 distinct AKAP9 gene products include 
a short isoform called Yotiao and long isoforms (AKAP350, AKAP450, and CG-NAP) 
often referred to collectively as AKAP450 based on their molecular weight(Wong and 
Scott). The shorter Yotaio form of the gene was first discovered from the library of 
cDNAs expressed in the human brain, where it is observed to play an important role in 
modulating both long term potentiation (LTP) and long term depression (LTD) of the 
synapses via regulation of PKA(Lin  et  al.;;  Sanderson  and  Dell’Acqua). Disruption of the 
binding of PKA and AKAPs (including AKAP5 and Yotiao) at nerve terminals in the 
hippocampus has been shown to interfere with cellular mechanisms associated with 
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spatial memory(Nie et al.). Additionally, at least one SNP in Yotiao has been previously 
implicated with causing a congenital heart abnormality characterized by long-QT 
intervals and arrhythmias, known as long-QT syndrome(L. Chen et al.). Noting that as 
many as 30% of AD patients also have some form of heart disease, the link between 
long-QT and AD risk may not be coincidental(Alzheimer’s Association).  Still, given that 
the locations of rs144662445 and rs149979685 are  approximately  38  kb  3’  and  61  kb  3’,  
respectively, from the boundaries of the Yotiao coding region we focused our attention 
on studying the relevance of the longer isoform of AKAP9 rather than further pursuing 
this potential connection between AD and long-QT syndrome.  Nonetheless we 
acknowledge this would be a worthwhile inquiry for some future investigation. 
While more is currently known about the Yotaio isoform of AKAP9, the locations 
of the two AKAP9 risk variants from our study, rs144662445 and rs149979685, are 
located over 35kb from the Yotiao coding region (see Figure 12). Hence it is more likely 
that the AD-associated AKAP9 variants affect the structure or function of AKAP450. 
AKAP450 is known to localize at the centrosomes of cells, and, like Yotiao, it is 
expressed in most tissues including brain(Witczak et al.). Studies have also shown that 
AKAP450 is involved in microtubule anchoring and organization at the 
centrosome(Keryer, Di Fiore, et al.) and necessary for the initiation of new microtubule 
formation on the cis-side of the golgi(Rivero et al.). Disrupted binding of AKAP450 to 
the centrosome interferes with centriole duplication and cell cycle progression(Keryer, 
Witczak, et al.). The non-synonymous change induced by rs144662445 (I2547M) is 5 
amino acids from the R2 binding site of AKAP450 (see Figure 12). Rs149979685 
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(S3767L) is located within the pericentrin/AKAP450 centrosomal targeting (PACT) 
domain  which  is  a  highly  conserved  region  near  the  3’  end  of  AKAP450 and is the region 
responsible for the localization of AKAP450 to the centrosome(Gillingham and Munro) 
(Figure 12). The role of AKAP450 in AD is unclear, however, it is worth noting that the 
protein has functional similarity with tau protein which is involved in microtubule 
stability and assembly and is a key constituent of neurofibrillary tangles which 
accumulate in AD brain(Iqbal et al.; Grundke-Iqbal, Iqbal, Tung, et al.; Grundke-Iqbal, 
Iqbal, Quinlan, et al.; Yoshida and Ihara). Reports also indicate that phosphorylated tau 
does not account for all of the microtubule loss and shortening observed in neurons of 
those with AD(Cash et al.). This and the known role AKAP9 plays as a scaffolding 
protein for PKA, an established regulator of synaptic plasticity, support the hypothesis 
that functional defects in AKAP450 may contribute to AD pathogenesis.   
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Figure 12: Common isoforms of AKAP9 
 
Figure 12 shows a side by side comparison of the two main isoforms of the AKAP9 
protein. Both rare AKAP9 variants identified in this analysis are found in the larger 
isoform, AKAP450, and not the shorter.  Rs144662445 (I2547M) falls within the R2-
binding site domain, while rs149979685 falls within the PACT domain of AKAP450.  
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3.5.2. Functional Prediction Results 
Noting both the generally high level of LD in the AKAP9 region and the observed 
correlation between rs144662445 and rs149979685, it is challenging to pinpoint which of 
the two protein coding changes is more likely to have a functional impact on AKAP9.  
However, a bioinformatic inquiry into this question using several methods suggests that 
rs149979685 is most likely to result in a functional change whereas the non-reference 
variant at rs144662445 is more likely to be benign (see Table 14). MutPred analysis also 
indicated that the likely cause of dysfunction brought on by the rs149979685 variant is 
loss of a helix (p=0.0033), but gain of a loop or loss of phosphorylation are also possible 
structural changes that might be induced by this change. Because the 3D structure of 
AKAP9 has yet to have been solved, the structural changes predicted by MutPred should 
be interpreted as purely hypothetical and additional work is needed to establish that these 
structures exist in the region surrounding rs149979685. Importantly, the two (probably 
private) AKAP9 variants in the 10000 genomes NA20298 sample (rs186619641 and 
rs201858518) were also predicted to be benign according to Polyphen-2. 
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Table 14: Bioinformatics Examination of the AD associated AKAP9 Variants 
 Polyphen-2 Sift MutPred 
SNP Score* Prediction Score† Prediction 
Probability 
Deleterious‡ 
Actionable 
Hypotheses‡ 
rs144662445 0.008 Benign 0.11 Tolerated 21% NA 
rs149979685 0.99 Probably Damaging 0.01 Damaging 57% 
Loss of helix       
(P = 0.0033) 
 
Gain of loop        
(P = 0.024 
 
Loss of 
phosphorylation                
(P = 0.029) 
 
  * In Polyphen-2 higher scores indicate that a SNP is more likely to be damaging.  
  †  In SIFT, lower scores indicate that a SNP is more likely to be deleterious.  
   ‡ In MutPred, a higher probability indicates that a SNP is more likely to be damaging.    
     Actionable hypotheses are predicted functional changes for which the probability  
     deleterious is <50% and for which the structural change P<.05.  
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3.6.  Conclusion 
3.6.1. Future replication experiments 
Our bioinformatic analysis indicates that rs149979685 is likely to have an adverse 
impact on the structure or post-translational modification of the AKAP protein, however, 
these results should be interpreted cautiously. Without functional data and supporting 
molecular work, we cannot definitively demonstrate that rs149979685 is the causal locus 
and/or whether rs144662445 is potentially causal due to some other mechanism not 
considered by the software used. Resolution of this question will require functional 
experimentation. In addition, targeted resequencing in both African- and European-
descent populations will be necessary to identify the full complement of genetic variants 
in order to provide greater understanding of the role that AKAP9 in AD pathogenesis. 
3.6.2. Utility of Exploratory Sequencing Experiments  
 We identified two AKAP9 SNPs which co-occur on a single background 
haplotype (HAP0) spanning AKAP9 and the surrounding area in a small WES study of 
seven familial AD cases. These SNPs were significantly enriched in AD cases compared 
to cognitively normal controls in a large African-American sample, and the associations 
were replicated in an even larger independent AA cohort. The magnitude of the effect of 
each of these variants on AD risk (OR of 2.75 and 3.61 respectively) in the replication 
cohort is larger than that reported for APOE 4 in African Americans (OR=2.31)(Reitz et 
al.). However, these missense variants are extremely rare in African American 
populations (ESP AA sample: MAFrs144662445=0.43% and MAFrs149979685=0.36%; 1000 
Genomes AFR sample: MAFrs144662445=0.81% and MAFrs149979685=0.61%). Moreover, 
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these variants have not been observed in non-African descent populations. Due to their 
low frequency, these AKAP9 variants do not explain much of the risk for AD in AAs, 
however, their discovery offers new insights into the molecular basis of this disease.  
Moreover, the successful identification and replication of these rare variants demonstrates 
the value of protocols, such as the one detailed in this chapter, which efficiently integrate 
the rare-variant detection capabilities of NGS technology with the established genotyping 
methods and publicly available genomic data to discover large-effect risk associations for 
common diseases. 
 
  
  
96 
REFERENCES 
Abecasis,  Goncalo  R  et  al.  “An  Integrated  Map  of  Genetic  Variation  from  1,092  Human  
Genomes.”  Nature 491.7422 (2012): 56–65. Web. 9 Jan. 2014. 
Adzhubei,  Ivan  A  et  al.  “A  Method  and  Server  for  Predicting  Damaging  Missense  
Mutations.”  Nature methods 7.4 (2010): 248–9. Web. 24 Jan. 2014. 
Alzheimer’s Association.  “2011  Alzheimer’s  Disease  Facts  and  Figures.”  Alzheimer’s  &  
dementia 7.2 (2011): 208–44. 
Aulchenko,  Yurii  S,  Maksim  V  Struchalin,  and  Cornelia  M  van  Duijn.  “ProbABEL  
Package for Genome-Wide Association  Analysis  of  Imputed  Data.”  BMC 
bioinformatics 11 (2010): 134. Web. 28 Jan. 2014. 
Bamshad,  Michael  J.  et  al.  “Exome  Sequencing  as  a  Tool  for  Mendelian  Disease  Gene  
Discovery.”  Nature Reviews Genetics 12.11 (2011): 745–755. Web. 9 Jan. 2014. 
Barnes, Deborah  E,  and  Kristine  Yaffe.  “The  Projected  Effect  of  Risk  Factor  Reduction  
on  Alzheimer’s  Disease  Prevalence.”  Lancet neurology 10.9 (2011): 819–28. Web. 
28 Jan. 2014. 
Bekris,  Lynn  M  et  al.  “Genetics  of  Alzheimer  Disease.”  Journal of geriatric psychiatry 
and neurology 23.4 (2010): 213–27. Web. 23 Jan. 2014. 
Bienvenu,  O  J,  D  S  Davydow,  and  K  S  Kendler.  “Psychiatric  ‘Diseases’  versus  
Behavioral  Disorders  and  Degree  of  Genetic  Influence.”  Psychological medicine 
41.1 (2011): 33–40. Web. 20 Feb. 2014. 
Browning, Brian  L,  and  Sharon  R  Browning.  “A  Unified  Approach  to  Genotype  
Imputation and Haplotype-Phase Inference for Large Data Sets of Trios and 
Unrelated  Individuals.”  American journal of human genetics 84.2 (2009): 210–23. 
Web. 23 Jan. 2014. 
Cantor, Rita M, Kenneth  Lange,  and  Janet  S  Sinsheimer.  “Prioritizing  GWAS  Results:  A  
Review  of  Statistical  Methods  and  Recommendations  for  Their  Application.”  
American journal of human genetics 86.1 (2010): 6–22. Web. 9 Jan. 2014. 
Cash,  Adam  D  et  al.  “Microtubule  Reduction  in Alzheimer’s  Disease  and  Aging  Is  
Independent  of  Tau  Filament  Formation.”  The American journal of pathology 162.5 
(2003): 1623–7. Web. 26 Feb. 2014. 
  
97 
Casserly,  Ivan,  and  Eric  Topol.  “Convergence  of  Atherosclerosis  and  Alzheimer’s  
Disease: Inflammation, Cholesterol,  and  Misfolded  Proteins.”  Lancet 363.9415 
(2004): 1139–46. Web. 28 Jan. 2014. 
Chen,  Lei  et  al.  “Mutation  of  an  A-Kinase-Anchoring Protein Causes Long-QT 
Syndrome.”  Proceedings of the National Academy of Sciences of the United States 
of America 104.52 (2007): 20990–5. Web. 25 Feb. 2014. 
Chen,  Wei  et  al.  “Genetic  Variants  near  TIMP3  and  High-Density Lipoprotein-
Associated Loci Influence Susceptibility to Age-Related  Macular  Degeneration.”  
Proceedings of the National Academy of Sciences of the United States of America 
107.16 (2010): 7401–6. Web. 27 Jan. 2014. 
Cheng,  Rong  et  al.  “Nonparametric  Disequilibrium  Mapping  of  Functional  Sites  Using  
Haplotypes of Multiple Tightly Linked Single-Nucleotide  Polymorphism  Markers.”  
1187.July (2003): 1175–1187. Print. 
Christenhusz,  Gabrielle  M,  Koenraad  Devriendt,  and  Kris  Dierickx.  “To  Tell  or  Not  to  
Tell? A Systematic Review of Ethical Reflections on Incidental Findings Arising in 
Genetics  Contexts.”  European  journal  of  human  genetics  :  EJHG 21.3 (2013): 248–
55. Web. 27 Jan. 2014. 
Cirulli,  Elizabeth  T,  and  David  B  Goldstein.  “Uncovering  the  Roles  of  Rare  Variants  in  
Common Disease through Whole-Genome  Sequencing.”  Nature reviews. Genetics 
11.6 (2010): 415–425. Web. 9 Jan. 2014. 
Clayton, David, and Hin-Tak  Leung.  “An  R  Package  for  Analysis  of  Whole-Genome 
Association  Studies.”  Human heredity 64.1 (2007): 45–51. Web. 28 Jan. 2014. 
Congdon,  Nathan  et  al.  “Causes  and  Prevalence  of  Visual  Impairment  among  Adults in 
the  United  States.”  Archives of ophthalmology 122.4 (2004): 477–85. Web. 27 Jan. 
2014. 
Connell,  Cathleen  M  et  al.  “Racial  Differences  in  Knowledge  and  Beliefs  about  
Alzheimer  Disease.”  Alzheimer disease and associated disorders 23.2 110–6. Web. 
24 Feb. 2014. 
Corder,  E  H  et  al.  “Protective  Effect  of  Apolipoprotein  E  Type  2  Allele  for  Late  Onset  
Alzheimer  Disease.”  Nature genetics 7.2 (1994): 180–4. Web. 24 Feb. 2014. 
DePristo,  Mark  A  et  al.  “A  Framework  for  Variation  Discovery  and  Genotyping  Using  
next-Generation  DNA  Sequencing  Data.”  Nature genetics 43.5 (2011): 491–8. Web. 
21 Jan. 2014. 
  
98 
Dharuri,  Harish  et  al.  “Automated  Workflow-Based Exploitation of Pathway Databases 
Provides  New  Insights  into  Genetic  Associations  of  Metabolite  Profiles.”  BMC 
genomics 14.1 (2013): 865. Web. 12 Jan. 2014. 
Dilworth-Anderson,  Peggye  et  al.  “Diagnosis  and  Assessment  of  Alzheimer’s  Disease  in  
Diverse  Populations.”  Alzheimer’s  &  dementia  :  the  journal  of  the  Alzheimer's  
Association 4.4 (2008): 305–9. Web. 24 Feb. 2014. 
Edwards,  Albert  O  et  al.  “Complement  Factor  H  Polymorphism  and  Age-Related 
Macular  Degeneration.”  Science (New York, N.Y.) 308.5720 (2005): 421–4. Web. 21 
Jan. 2014. 
“Exome  Variant  Server,  NHLBI  GO  Exome  Sequencing  Project  (ESP),  Seattle,  WA  
(URL: http://evs.gs.washington.edu/EVS/)  [Jan.,  2014].”  N.  p.,  n.d. 
Fagerness,  Jesen  A  et  al.  “Variation  near  Complement  Factor  I  Is  Associated  with  Risk  of  
Advanced  AMD.”  European  journal  of  human  genetics  :  EJHG 17.1 (2009): 100–4. 
Web. 28 Jan. 2014. 
Freedman,  Matthew  L  et  al.  “Assessing  the  Impact  of  Population  Stratification  on  
Genetic  Association  Studies.”  Nature genetics 36.4 (2004): 388–93. Web. 17 Jan. 
2014. 
Fritsche,  Lars  G  et  al.  “Seven  New  Loci  Associated  with  Age-Related Macular 
Degeneration.”  Nature genetics 45.4 (2013): 433–9, 439e1–2. Web. 28 Jan. 2014. 
Frousios,  Kimon  et  al.  “Predicting  the  Functional  Consequences  of  Non-Synonymous 
DNA Sequence Variants--Evaluation of Bioinformatics Tools and Development of a 
Consensus  Strategy.”  Genomics 102.4 (2013): 223–8. Web. 9 Jan. 2014. 
Gibson,  Greg.  “Rare  and  Common  Variants:  Twenty  Arguments.”  Nature reviews. 
Genetics 13.2 (2011): 135–45. Web. 9 Jan. 2014. 
Gillingham, A  K,  and  S  Munro.  “The  PACT  Domain,  a  Conserved  Centrosomal  
Targeting Motif in the Coiled-Coil  Proteins  AKAP450  and  Pericentrin.”  EMBO 
reports 1.6 (2000): 524–9. Web. 26 Feb. 2014. 
Gold,  Bert  et  al.  “Variation  in  Factor  B  (BF)  and  Complement  Component  2  (C2) Genes 
Is Associated with Age-Related  Macular  Degeneration.”  Nature genetics 38.4 
(2006): 458–62. Web. 28 Jan. 2014. 
Goldman,  Jill  S  et  al.  “Genetic  Counseling  and  Testing  for  Alzheimer  Disease:  Joint  
Practice Guidelines of the American College of Medical Genetics and the National 
  
99 
Society  of  Genetic  Counselors.”  Genetics  in  medicine  :  official  journal  of  the  
American College of Medical Genetics 13.6 (2011): 597–605. Web. 31 Jan. 2014. 
Graff-Radford,  Neill  R  et  al.  “Association  between  Apolipoprotein  E  Genotype and 
Alzheimer  Disease  in  African  American  Subjects.”  Archives of neurology 59.4 
(2002): 594–600. Web. 24 Feb. 2014. 
Green,  Robert  C  et  al.  “Risk  of  Dementia  among  White  and  African  American  Relatives  
of  Patients  with  Alzheimer  Disease.”  JAMA  :  the  journal of the American Medical 
Association 287.3 (2002): 329–36. Web. 27 Mar. 2014. 
Grundke-Iqbal,  I,  K  Iqbal,  Y  C  Tung,  et  al.  “Abnormal  Phosphorylation  of  the  
Microtubule-Associated  Protein  Tau  (tau)  in  Alzheimer  Cytoskeletal  Pathology.”  
Proceedings of the National Academy of Sciences of the United States of America 
83.13 (1986): 4913–7. Web. 20 Feb. 2014. 
Grundke-Iqbal,  I,  K  Iqbal,  M  Quinlan,  et  al.  “Microtubule-Associated Protein Tau. A 
Component  of  Alzheimer  Paired  Helical  Filaments.”  The Journal of biological 
chemistry 261.13 (1986): 6084–9. Web. 21 Feb. 2014. 
Haupt,  Jarvis,  Rui  M  Castro,  and  Robert  Nowak.  “Distilled  Sensing  :  Adaptive  Sampling  
for  Sparse  Detection  and  Estimation.”  IEEE Transactions on Information Theory 
57.9 (2011): 6222–6235. Print. 
Helisalmi,  Seppo  et  al.  “ADAMTS9  Locus  Associates  with  Increased  Risk  of  Wet  
AMD.”  Acta ophthalmologica (2014): n. pag. Web. 12 Feb. 2014. 
Hindorff,  Lucia  A  et  al.  “Potential  Etiologic  and  Functional  Implications  of  Genome-
Wide  Association  Loci  for  Human  Diseases  and  Traits.”  Proceedings of the 
National Academy of Sciences of the United States of America 106.23 (2009): 9362–
7. Web. 10 Jan. 2014. 
Holmans,  Peter  et  al.  “Gene  Ontology  Analysis  of  GWA  Study  Data  Sets  Provides  
Insights  into  the  Biology  of  Bipolar  Disorder.”  American journal of human genetics 
85.1 (2009): 13–24. Web. 21 Jan. 2014. 
Holtzman, David M, John C Morris, and  Alison  M  Goate.  “Alzheimer’s  Disease:  The  
Challenge  of  the  Second  Century.”  Science translational medicine 3.77 (2011): 
77sr1. Web. 20 Feb. 2014. 
Hou,  Lin,  and  Hongyu  Zhao.  “A  Review  of  Post-GWAS  Prioritization  Approaches.”  
Frontiers in genetics 4.December (2013): 280. Web. 10 Jan. 2014. 
  
100 
Hyman,  L  et  al.  “Hypertension,  Cardiovascular  Disease,  and  Age-Related Macular 
Degeneration. Age-Related  Macular  Degeneration  Risk  Factors  Study  Group.”  
Archives of ophthalmology 118.3 (2000): 351–8. Web. 28 Jan. 2014. 
Illig,  Thomas  et  al.  “A  Genome-Wide Perspective of Genetic Variation in Human 
Metabolism.”  Nature genetics 42.2 (2010): 137–41. Web. 12 Jan. 2014. 
International  HapMap  Consortium.  “A  Haplotype  Map  of  the  Human  Genome.”  Nature 
437.7063 (2005): 1299–320. Web. 20 Jan. 2014. 
Ioannidis,  John  P  A.  “Why  Most  Discovered  True  Associations  Are  Inflated.”  
Epidemiology (Cambridge, Mass.) 19.5 (2008): 640–8. Web. 22 Jan. 2014. 
Iqbal,  K  et  al.  “Defective  Brain  Microtubule  Assembly  in  Alzheimer’s  Disease.”  Lancet 
2.8504 (1986): 421–6. Web. 26 Feb. 2014. 
Jakobsdottir,  Johanna  et  al.  “Susceptibility  Genes  for  Age-Related Maculopathy on 
Chromosome  10q26.”  American journal of human genetics 77.3 (2005): 389–407. 
Web. 28 Jan. 2014. 
Jing,  Author  et  al.  “Gap:  Genetic  Analysis Package. R Package Version 1.1-10.”  2013  :  n.  
pag. Print. 
Keryer,  Guy,  Oliwia  Witczak,  et  al.  “Dissociating  the  Centrosomal  Matrix  Protein  
AKAP450 from Centrioles Impairs Centriole Duplication and Cell Cycle 
Progression.”  Molecular biology of the cell 14.6 (2003): 2436–46. Web. 4 Feb. 
2014. 
Keryer,  Guy,  Barbara  Di  Fiore,  et  al.  “Part  of  Ran  Is  Associated  with  AKAP450  at  the  
Centrosome: Involvement in Microtubule-Organizing  Activity.”  Molecular biology 
of the cell 14.10 (2003): 4260–71. Web. 26 Feb. 2014. 
Khoury,  Muin  J  et  al.  “On  the  Synthesis  and  Interpretation  of  Consistent  but  Weak  Gene-
Disease Associations in the Era of Genome-Wide  Association  Studies.”  
International journal of epidemiology 36.2 (2007): 439–45. Web. 12 Jan. 2014. 
Kinoshita, June, and  Timothy  Clark.  “Alzforum.”  Methods in molecular biology (Clifton, 
N.J.) 401 (2007): 365–81. Web. 20 Feb. 2014. 
Klaver,  C  C  et  al.  “Is  Age-Related  Maculopathy  Associated  with  Alzheimer’s  Disease?  
The  Rotterdam  Study.”  American journal of epidemiology 150.9 (1999): 963–8. 
Web. 12 Jan. 2014. 
  
101 
Klein,  R  et  al.  “The  Beaver  Dam  Eye  Study:  The  Relation  of  Age-Related Maculopathy 
to  Smoking.”  American journal of epidemiology 137.2 (1993): 190–200. Web. 28 
Jan. 2014. 
Klein,  Robert  J  et  al.  “Complement  Factor  H  Polymorphism in Age-Related Macular 
Degeneration.”  Science (New York, N.Y.) 308.5720 (2005): 385–9. Web. 20 Jan. 
2014. 
Koo, Bon-Hun  et  al.  “ADAMTS9  Is  a  Cell-Autonomously Acting, Anti-Angiogenic 
Metalloprotease  Expressed  by  Microvascular  Endothelial  Cells.”  The American 
journal of pathology 176.3 (2010): 1494–504. Web. 6 Feb. 2014. 
Laird,  N  M,  S  Horvath,  and  X  Xu.  “Implementing  a  Unified  Approach  to  Family-Based 
Tests  of  Association.”  Genetic epidemiology 19 Suppl 1 (2000): S36–42. Web. 9 
Jan. 2014. 
Lau, Chun H et  al.  “Acute  Retinal  Necrosis  Features,  Management,  and  Outcomes.”  
Ophthalmology 114.4 (2007): 756–62. Web. 12 Feb. 2014. 
Leoni,  Valerio.  “The  Effect  of  Apolipoprotein  E  (ApoE)  Genotype  on  Biomarkers  of  
Amyloidogenesis, Tau Pathology and Neurodegeneration  in  Alzheimer’s  Disease.”  
Clinical  chemistry  and  laboratory  medicine  :  CCLM  /  FESCC 49.3 (2011): 375–83. 
Web. 20 Feb. 2014. 
Li,  Chun,  and  Mingyao  Li.  “GWAsimulator:  A  Rapid  Whole-Genome Simulation 
Program.”  Bioinformatics (Oxford, England) 24.1 (2008): 140–2. Web. 26 Jan. 
2014. 
Li, Heng,  and  Richard  Durbin.  “Fast  and  Accurate  Long-Read Alignment with Burrows-
Wheeler  Transform.”  Bioinformatics (Oxford, England) 26.5 (2010): 589–95. Web. 
19 Feb. 2014. 
Li,  Mingyao  et  al.  “CFH  Haplotypes  without  the  Y402H  Coding  Variant  Show  Strong  
Association with Susceptibility to Age-Related  Macular  Degeneration.”  Nature 
genetics 38.9 (2006): 1049–54. Web. 28 Jan. 2014. 
Li,  Yun,  Cristen  Willer,  et  al.  “Genotype  Imputation.”  Annual review of genomics and 
human genetics 10 (2009): 387–406. Web. 22 Jan. 2014. 
Li,  Yun,  Cristen  J  Willer,  et  al.  “MaCH:  Using  Sequence  and  Genotype  Data  to  Estimate  
Haplotypes  and  Unobserved  Genotypes.”  Genetic epidemiology 34.8 (2010): 816–
34. Web. 22 Jan. 2014. 
  
102 
Lin,  J  W  et  al.  “Yotiao,  a  Novel  Protein  of  Neuromuscular  Junction and Brain That 
Interacts  with  Specific  Splice  Variants  of  NMDA  Receptor  Subunit  NR1.”  The 
Journal  of  neuroscience  :  the  official  journal  of  the  Society  for  Neuroscience 18.6 
(1998): 2017–27. Web. 25 Feb. 2014. 
Logue,  M  et  al.  “A  Comprehensive  Genetic  Association  Study  of  Alzheimer  Disease  in  
African  Americans.”  Archives of neurology 68.12 (2011): 1569–79. Web. 12 Feb. 
2014. 
Logue,  Mark  W.  et  al.  “A  Search  for  AMD  Risk  Variants  in  Alzheimer  Disease  Genes  
and  Pathways.”  Neurobiology of Aging (2013): n. pag. Web. 11 Jan. 2014. 
Maller,  Julian  et  al.  “Common  Variation  in  Three  Genes,  Including  a  Noncoding Variant 
in CFH, Strongly Influences Risk of Age-Related  Macular  Degeneration.”  Nature 
genetics 38.9 (2006): 1055–9. Web. 28 Jan. 2014. 
Maller,  Julian  B  et  al.  “Variation  in  Complement  Factor  3  Is  Associated  with  Risk  of  
Age-Related Macular Degeneration.”  Nature genetics 39.10 (2007): 1200–1. Web. 
28 Jan. 2014. 
Manolio,  Teri  a  et  al.  “Finding  the  Missing  Heritability  of  Complex  Diseases.”  Nature 
461.7265 (2009): 747–53. Web. 9 Jan. 2014. 
Marchini,  Jonathan  et  al.  “A  New  Multipoint  Method  for  Genome-Wide Association 
Studies  by  Imputation  of  Genotypes.”  Nature genetics 39.7 (2007): 906–13. Web. 
20 Jan. 2014. 
McKenna,  Aaron  et  al.  “The  Genome  Analysis  Toolkit:  A  MapReduce  Framework  for  
Analyzing next-Generation  DNA  Sequencing  Data.”  Genome research 20.9 (2010): 
1297–303. Web. 19 Feb. 2014. 
Montefusco,  Laura  B,  Damiana  Lazzaro,  and  Serena  Papi.  “Adaptive  Nonlinear  
Filtering.”  20.2  (2011):  534–544. Print. 
Newman,  Howard,  and  Caroline  Gooding.  “Viral  Ocular  Manifestations:  A  Broad  
Overview.”  Reviews in medical virology 23.5 (2013): 281–94. Web. 12 Feb. 2014. 
Ng,  P  C,  and  S  Henikoff.  “Predicting  Deleterious  Amino  Acid  Substitutions.”  Genome 
research 11.5 (2001): 863–74. Web. 29 Jan. 2014. 
Nicolae,  Dan  L  et  al.  “Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation 
to  Enhance  Discovery  from  GWAS.”  PLoS genetics 6.4 (2010): e1000888. Web. 11 
Jan. 2014. 
  
103 
Nie,  Ting  et  al.  “Genetic  Disruption  of  Protein  Kinase  A  Anchoring  Reveals  a  Role  for  
Compartmentalized Kinase Signaling in Theta-Burst Long-Term Potentiation and 
Spatial  Memory.”  The  Journal  of  neuroscience  :  the  official  journal  of  the  Society  
for Neuroscience 27.38 (2007): 10278–88. Web. 31 Jan. 2014. 
Pallejà,  Albert  et  al.  “DistiLD  Database:  Diseases  and  Traits  in  Linkage  Disequilibrium  
Blocks.”  Nucleic acids research 40.Database issue (2012): D1036–40. Web. 20 Jan. 
2014. 
Pattnaik,  Swetansu  et  al.  “Customisation  of  the  Exome  Data  Analysis  Pipeline  Using  a  
Combinatorial  Approach.”  Ed.  Paolo  Provero.  PloS one 7.1 (2012): e30080. Web. 
20 Feb. 2014. 
Price,  Alkes  L  et  al.  “Principal  Components Analysis Corrects for Stratification in 
Genome-Wide  Association  Studies.”  Nature genetics 38.8 (2006): 904–9. Web. 20 
Feb. 2014. 
Purcell,  Shaun  et  al.  “PLINK:  A  Tool  Set  for  Whole-Genome Association and 
Population-Based  Linkage  Analyses.”  American journal of human genetics 81.3 
(2007): 559–75. Web. 21 Jan. 2014. 
Reitz,  Christiane  et  al.  “Variants  in  the  ATP-Binding Cassette Transporter (ABCA7), 
Apolipoprotein E ϵ4,and the Risk of Late-Onset Alzheimer Disease in African 
Americans.”  JAMA  :  the  journal of the American Medical Association 309.14 
(2013): 1483–92. Web. 23 Jan. 2014. 
“Risk  Factors  for  Neovascular  Age-Related Macular Degeneration. The Eye Disease 
Case-Control  Study  Group.”  Archives of ophthalmology 110.12 (1992): 1701–8. 
Web. 28 Jan. 2014. 
Rivera,  Andrea  et  al.  “Hypothetical  LOC387715  Is  a  Second  Major  Susceptibility  Gene  
for Age-Related Macular Degeneration, Contributing Independently of Complement 
Factor  H  to  Disease  Risk.”  Human molecular genetics 14.21 (2005): 3227–36. Web. 
28 Jan. 2014. 
Rivero,  Sabrina  et  al.  “Microtubule  Nucleation  at  the  Cis-Side of the Golgi Apparatus 
Requires  AKAP450  and  GM130.”  The EMBO journal 28.8 (2009): 1016–28. Web. 
20 Feb. 2014. 
Roberts,  J  S,  K  D  Christensen,  and  R  C  Green.  “Using  Alzheimer’s  Disease  as  a  Model 
for  Genetic  Risk  Disclosure:  Implications  for  Personal  Genomics.”  Clinical genetics 
80.5 (2011): 407–14. Web. 29 Jan. 2014. 
  
104 
Rossin,  Elizabeth  J  et  al.  “Proteins  Encoded  in  Genomic  Regions  Associated  with  
Immune-Mediated Disease Physically Interact and Suggest  Underlying  Biology.”  
Ed. Takashi Gojobori. PLoS genetics 7.1 (2011): e1001273. Web. 22 Jan. 2014. 
Sanderson,  Jennifer  L,  and  Mark  L  Dell’Acqua.  “AKAP  Signaling  Complexes  in  
Regulation  of  Excitatory  Synaptic  Plasticity.”  The  Neuroscientist  :  a  review  journal  
bringing neurobiology, neurology and psychiatry 17.3 (2011): 321–36. Web. 25 
Feb. 2014. 
Satoh,  Takeshi,  and  Hisashi  Arase.  “HSV-1 Infection through Inhibitory Receptor, 
PILRalpha.”  Uirusu 58.1 (2008): 27–36. Web. 12 Feb. 2014. 
Saunders,  A  M  et  al.  “Association  of  Apolipoprotein  E  Allele  Epsilon  4  with  Late-Onset 
Familial  and  Sporadic  Alzheimer’s  Disease.”  Neurology 43.8 (1993): 1467–72. 
Web. 24 Feb. 2014. 
Schu,  Matthew  C  et  al.  “The  Genetics  of  Alzheimer  ’  S  Sonal.”  Alzheimer’s  Disease  – 
Modernizing Concept, Biological Diagnosis and Therapy. Ed. H Hampel and MC 
Carrillo. Vol. 28. Basel: Karger, 2012. 15–29. Print. 
Shental,  Noam,  Amnon  Amir,  and  Or  Zuk.  “Identification  of  Rare  Alleles  and  Their  
Carriers Using Compressed Se(que)nsing.”  Nucleic acids research 38.19 (2010): 
e179. Web. 17 Jan. 2014. 
Shiratori,  Ikuo  et  al.  “Activation  of  Natural  Killer  Cells  and  Dendritic  Cells  upon  
Recognition of a Novel CD99-like Ligand by Paired Immunoglobulin-like Type 2 
Receptor.”  The Journal of experimental medicine 199.4 (2004): 525–33. Web. 12 
Feb. 2014. 
Shukla,  Shripaad  Y,  Yogesh  K  Singh,  and  Deepak  Shukla.  “Role  of  Nectin-1, HVEM, 
and PILR-Alpha in HSV-2  Entry  into  Human  Retinal  Pigment  Epithelial  Cells.”  
Investigative ophthalmology & visual science 50.6 (2009): 2878–87. Web. 12 Feb. 
2014. 
Van  Leeuwen,  Redmer  et  al.  “Blood  Pressure,  Atherosclerosis,  and  the  Incidence  of  Age-
Related  Maculopathy:  The  Rotterdam  Study.”  Investigative ophthalmology & visual 
science 44.9 (2003): 3771–7. Web. 28 Jan. 2014. 
Wang,  Kai,  Mingyao  Li,  and  Maja  Bucan.  “Pathway-Based Approaches for Analysis of 
Genomewide  Association  Studies.”  The American Journal of Human Genetics 81.6 
(2007): 1278–1283. Web. 14 Jan. 2014. 
  
105 
Wang,  Lily  et  al.  “Gene  Set  Analysis  of  Genome-Wide Association Studies: 
Methodological  Issues  and  Perspectives.”  Genomics 98.1 (2011): 1–8. Web. 13 Jan. 
2014. 
Whitmore,  S  Scott  et  al.  “Altered  Gene  Expression  in  Dry  Age-Related Macular 
Degeneration  Suggests  Early  Loss  of  Choroidal  Endothelial  Cells.” Molecular vision 
19 (2013): 2274–97. Web. 12 Feb. 2014. 
Wigle,  Dennis  A.  “Biologic  Approaches  to  Drug  Selection  and  Targeted  Therapy:  Hype  
or  Clinical  Reality?”  Thoracic surgery clinics 23.3 (2013): 421–8. Web. 30 Jan. 
2014. 
Willer, Cristen J, Yun Li, and Gonçalo  R  Abecasis.  “METAL:  Fast  and  Efficient  Meta-
Analysis  of  Genomewide  Association  Scans.”  Bioinformatics (Oxford, England) 
26.17 (2010): 2190–1. Web. 21 Jan. 2014. 
Witczak,  O  et  al.  “Cloning  and  Characterization  of  a  cDNA  Encoding  an  A-Kinase 
Anchoring  Protein  Located  in  the  Centrosome,  AKAP450.”  The EMBO journal 18.7 
(1999): 1858–68. Web. 4 Feb. 2014. 
Wong,  Wei,  and  John  D  Scott.  “AKAP  Signalling  Complexes:  Focal  Points  in  Space  and  
Time.”  Nature reviews. Molecular cell biology 5.12 (2004): 959–70. Web. 19 Feb. 
2014. 
Wray,  Naomi  R,  Michael  E  Goddard,  and  Peter  M  Visscher.  “Prediction  of  Individual  
Genetic  Risk  of  Complex  Disease.”  Current opinion in genetics & development 18.3 
(2008): 257–63. Web. 21 Jan. 2014. 
Yaspan,  Brian  L  et  al.  “Genetic  Analysis of Biological Pathway Data through Genomic 
Randomization.”  Human genetics 129.5 (2011): 563–71. Web. 12 Jan. 2014. 
Yates,  John  R  W  et  al.  “Complement  C3  Variant  and  the  Risk  of  Age-Related Macular 
Degeneration.”  The New England journal of medicine 357.6 (2007): 553–61. Web. 
28 Jan. 2014. 
Yoshida,  H,  and  Y  Ihara.  “Tau  in  Paired  Helical  Filaments  Is  Functionally  Distinct  from  
Fetal Tau: Assembly Incompetence of Paired Helical Filament-Tau.”  Journal of 
neurochemistry 61.3 (1993): 1183–6. Web. 26 Feb. 2014. 
Yu,  Yi  et  al.  “Common  Variants  near  FRK/COL10A1  and  VEGFA  Are  Associated  with  
Advanced Age-Related  Macular  Degeneration.”  Human molecular genetics 20.18 
(2011): 3699–709. Web. 28 Jan. 2014. 
  
106 
Yuan, Hsiang-Yu  et  al.  “FASTSNP:  An  Always  up-to-Date and Extendable Service for 
SNP  Function  Analysis  and  Prioritization.”  Nucleic acids research 34.Web Server 
issue (2006): W635–41. Web. 11 Jan. 2014. 
Zeger,  S  L,  and  K  Y  Liang.  “Longitudinal  Data  Analysis  for  Discrete  and  Continuous  
Outcomes.”  Biometrics 42.1 (1986): 121–30. Web. 25 Jan. 2014. 
Zeger,  S  L,  K  Y  Liang,  and  P  S  Albert.  “Models  for  Longitudinal  Data:  A  Generalized  
Estimating  Equation  Approach.”  Biometrics 44.4 (1988): 1049–60. Web. 9 Jan. 
2014. 
 
  
  
107 
CURRICULUM VITAE 
 Matthew Charles Schu 
mcschu@bu.edu  
   
EDUCATION 
PhD in Bioinformatics      Boston University / Boston, MA 
May 2014 
M.S. in Bioinformatics      Boston University / Boston, MA 
May 2012 
M.S. in Education     Simmons College / Boston, MA  
May 2006  
B.S. in Physics & Mathematics      William & Mary / Williamsburg, VA 
             May 2003 – Summa Cum Laude  
 
COMPUTER SKILLS 
Scripting / Algorithm Development              C++, Perl, Python and R 
Statistical Analysis / Visualization          R, WEKA, Matlab, SAS, and Excel 
Data Storage / Management                           MySQL and PostgreSQL 
Web Programming                       HTML, Perl-CGI, and CSS 
 
SELECTED PUBLICATIONS 
 Logue MW, Schu M, Vardarajan BN, Farrell J, Lunetta KL, Jun G, Baldwin 
CT, Deangelis MM, Farrer LA. A search for age-related macular degeneration 
risk variants in Alzheimer disease genes and pathways. Neurobiology of 
Aging. 2013 Dec 19. doi: 10.1016/j.neurobiolaging.2013.12.007. [Epub ahead 
of print] 
 
  
108 
 M Schu,  RC  Green.    Alzheimer’s  Disease;;  Clinical Genomics: Practical 
Applications in Adult Patient Care. McGraw-Hill Publishers. 2013 Oct; 
chapter 124. 
 
 Fritsche LG, Chen W, Schu M, Yaspan BL, et al., Seven new loci associated 
with age-related macular degeneration. Nature Genetics. 2013 Apr;45(4):433-
439. 
 
 Schu M,  R  Sherva,  LA  Farrer,  RC  Green.  Alzheimer’s  Disease  – 
Modernizing Concept, Biological Diagnosis and Therapy. Adv Biol 
Psychiatry. Basel, Karger, 2012, vol 28. Hampel H, Carrillo MC (eds). 
 
 Logue MW, Schu M, Vardarajan BN, et al. A Comprehensive Genetic 
Association  Study  of  Alzheimer’s  Disease  in  African  Americans.  Archives  of  
Neurology. 2011. Dec;68(12):1569-1579. 
 
 Henson SM, Reilly JR, Robertson SL, Schu M, Davis EW, and Cushing JM. 
Predicting Irregularities in Population Cycles. SIAM Journal of Applied 
Dynamical Systems. 2003. vol 2; no.2: 238-253.  
 
 Schu M. External Cavity Diode Lasers: Controlling Laser Output via Optical 
Feedback. 2003. William and Mary press. (undergraduate honors thesis) 
 
PRESENTATIONS AT RECENT CONFERENCES 
 Logue MW, Schu M, Vardarajan BN, Farrell J, Kathryn L, Baldwin CT, 
Fallin MD, Farrer LA. Role of Rare Variation in Risk for AD. Oral 
presentation at the AAIC Meeting, July 16, 2013, Boston, MA. 
 
 Schu M, Chen W, Fritsche L, Yi Y,Yaspan B, AMDgene Consortium. Meta-
analysis of genome-wide association studies identifies 19 loci associated with 
AMD risk Presented at the 2012 Association of Research in Vision and 
Ophthalmology (ARVO) Meeting. May 7, 2012, Fort Lauderdale, FL 
 
 Schu M, Jun G, Morrison MA, Farrell J, Kim IK, Morgan DJ, Hagman GS, 
Farrer LA, DeAngelis MM. Genome-wide association study reveals 
genetically distinct phenotypic subtypes of age-related macular degeneration. 
Abstract presented at the ICHG/ASHG Meeting, October 13, 2011, Montreal, 
Canada. 
 
 Logue MW, Schu M, Vardarajan BN, Farrell J, Baldwin CT, Farrer LA. 
Prioritization of novel variants through whole-exome sequencing and pathway 
discover  in  Alzheimer’s  Disease.  Abstract  presented  at  the  ICHG/ASHG  
Meeting, October 13, 2011, Montreal, Canada. 
 
 Chen W, Fritsche L, Yi Y, Schu M, Yaspan B, AMDgene Consortium.  Meta-
analysis of 15 genome-wide association studies with ~8,000 cases and 
  
109 
~50,000 controls identified multiple novel loci asociated with age related 
macular degeneration. Abstract presented at the ICHG/ASHG Meeting, 
October 13, 2011, Montreal, Canada 
 
 Schu M, Vardarajan BN, Baldwin CT, Lunetta K, Buros J, Green RC, 
Cupples LA,  Fallin D, Farrer LA, Logue MW. Genome-wide association 
study  of  Alzheimer’s  disease  in  African  Americans  provides  evidence  of  
association with novel variants in CLU and PICALM. Abstract presented at 
the presented the 8th Annual  Alzheimer’s  Disease  Day,  September  21,  2010,  
BUMC, Boston, MA.  
 
EDUCATOR EXPERIENCE 
Firehoze    Online Instructor & Instructor Trainer, 2010 – 2011  
 Online Video Tutorials: Developed brief (10-15min) video tutorials to teach 
basic principles in physics and high school upper-level math. 
 Tutor Training: Led hour-long trainings aimed at helping new tutors improve 
content and presentation of lessons. 
 
Landmark School         High School Educator, 2003 – 2008   
 Math & Science Teacher: Courses tough include physics, chemistry, physical 
science, physics of technology, calculus I & II, pre-calculus, algebra II and 
reading tutorial. 
 Summer Residential Coordinator: Managed residential activities of campus 
during summer session.  
 
GRADUATE STUDENT BODY VOLUNTEER WORK 
  The BU Bioinformatics Student Organized Symposium      2009 – 2010   
 Committee Chair: Coordinated elections to generate a list of nominees 
representative of the interests of the entire student body.  Inviting speakers 
and  planned  the  schedule  of  the  day’s  events.  Also  coordinated  travel  
schedules and accommodation for guests.  
 
 
 
 
 
